What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2026-04-13 compared with 2025-03-28 · 268 added, 1026 removed, 23 unchanged (98% of the section changed)

ALT5 Sigma Corporation, (formerly known as JanOne Inc.) and subsidiaries (collectively, “we,” “us,” the “Company,” or “ALT5”).

Through our Fintech segment, the Company provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm, and, through our Biotechnology segment, we are focused on finding treatments for conditions that cause chronic pain and bringing to market drugs with non-addictive and non-sedative pain-relieving properties.

On May 15, 2024, the Company acquired ALT5 Sigma, Inc., and on July 15, 2024, changed its corporate name from JanOne Inc.

to ALT5 Sigma Corporation.

Sigma Corporation (formerly known as JanOne Inc.) and subsidiaries (collectively, “we,” “us,” the “Company,”

Through our Fintech segment, the Company provides next-generation blockchain-powered technologies for digital

asset trading, payments processing and related payment card services.

May 15, 2024, the Company acquired ALT5 Sigma, Inc., and on July 15, 2024, changed its corporate name from JanOne Inc.

to ALT5 Sigma

ALT5 Sigma, Inc., is a financial services and Fintech holding company.

ALT5 Sigma, Inc.

was created by financial industry specialists out of the necessity to provide the digital asset economy with the best practices of the industry and state of the art over-the-counter trading.

Through March 8, 2023, the Company operated its discontinued legacy businesses through its Recycling Subsidiaries, consisting of:

(a) ARCA Recycling, Inc., a California corporation (“ARCA Recycling”), (b) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada (“ARCA Canada”), and (c) Customer Connexx, LLC, a Nevada limited liability company (“Connexx”).

ARCA Recycling and ARCA Canada recycle major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs.

Connexx is a company that provides call center services for recycling businesses.

On March 9, 2023, we entered into a Stock Purchase Agreement (the “Recycling Purchase Agreement”) with VM7 Corporation, a Delaware corporation (“VM7”), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries.

was created by financial industry

specialists to provide the digital asset economy with the best practices of the industry and state of the art over-the-counter trading.

May 9, 2025, the Company acquired Fortress II Holdings Ltd.

d/b/a Mswipe.

Mswipe is a next-generation payment solutions provider offering

multi-currency, fiat payment card services, along with crypto-enabled capabilities through its existing integration with the ALT5 Subsidiary

Its suite of physical and virtual cards, available on both the Visa ® and Mastercard ® networks,

allows users seamlessly to spend traditional and digital currencies worldwide (see Note 3).

March 8, 2023, the Company operated its legacy businesses, which are now discontinued operations, through its Recycling Subsidiaries,

consisting of:

(a) ARCA Recycling, Inc., a California corporation (“ARCA Recycling”), (b) ARCA Canada Inc., a corporation

organized under the laws of Ontario, Canada (“ARCA Canada”), and (c) Customer Connexx, LLC, a Nevada limited liability company

ARCA Recycling and ARCA Canada recycled major household appliances in North America by providing turnkey appliance

recycling and replacement services for utilities and other sponsors of energy efficiency programs.

Connexx was a company that provided

call center services for recycling businesses.

On March 9, 2023, we entered into a Stock Purchase Agreement (the “Recycling Purchase

Agreement”) with VM7 Corporation, a Delaware corporation (“VM7”), under which it agreed to acquire all of the outstanding

equity interests of the Recycling Subsidiaries.

The principal of VM7 is Virland A.

Johnson, our Chief Financial Officer.

The information contained in or accessible from our website is not incorporated into this Annual Report on Form 10-K (the “Form 10-K”), and it should not be considered part of this Form 10-K.

We have included our website address in this Form 10-K solely as an inactive textual reference.

The Company’s legal address is located at 325 E Warm Springs Rd #102, Las Vegas, NV 89119, with subsidiary offices in Newmarket, and Montreal, Canada.

ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms to its customers:

“ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs.

Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets.

Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat.

ALT5 Prime is available through a browser-based access, mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

ALT5 Sigma, Inc., has two wholly owned subsidiaries, ALT5 Sigma Canada, Inc., and ALT5 Securities, Inc.

Johnson, our former Chief Financial Officer.

information contained in or accessible from our website is not incorporated into this Annual Report on Form 10-K (the “Form 10-K”),

and it should not be considered part of this Form 10-K.

We have included our website address in this Form 10-K solely as an inactive

textual reference.

Company’s principal executive offices are is located at 8958 Rozita Lee Ave., #305, Las Vegas, Nevada 89113, with subsidiary offices

in Newmarket and Montreal, Canada

Sigma, Inc., through its subsidiaries, offers three main platforms to its customers:

“ALT5 Pay”, “ALT5 Prime”,

and “StrataCarte”.

ALT5 Pay is a cryptocurrency payment gateway that enables registered and approved global merchants to

accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the

plugins with WooCommerce and/or ALT5 Pay’s checkout widgets and APIs.

Merchants have the option to convert to fiat currency (U.S.

Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets.

is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets.

can purchase digital assets with fiat and, equally, sell digital assets and receive fiat.

ALT5 Prime is available through a browser-based

application, a mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, and Google Play,

through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

is a next-generation payment solutions provider offering multi-currency, fiat payment card services, along with crypto-enabled capabilities

through its existing integration with the ALT5 Subsidiary platform.

Its suite of physical and virtual cards, available on both the Visa ®

and Mastercard ® networks, allows users to seamlessly spend traditional and digital currencies worldwide.

Sigma, Inc., has two wholly-owned subsidiaries, ALT5 Sigma Canada, Inc., and ALT5Sigma Markets, Inc.

ALT5 Sigma Canada, Inc.

has four wholly owned subsidiaries, ALT5 AI, Inc.

wholly-owned subsidiaries, ALT5 AI, Inc.

(Canada), ALT5 Pro, LLC.

(Saint-Vincent and the Grenadines), UAB ALT5 Sigma Prudentia (Lithuania), and ALT5 Sigma Prudentia s.r.o.

(Czech Republic) formerly Cypherlynx s.r.o.

ALT5 Sigma develops, commercializes products and services based on four key fundamental principles of 1) Safety, Security and Trust, 2) Accessibility 3) Regulations, 4) Transparency:

Safety, Security and Trust

Develop and deploy products and services that increase our clients and customers' trust in our organization.

(Saint Vincent and the Grenadines), and ALT5 ATM, Inc.

Sigma develops and commercializes products and services based on four key fundamental principles of (i) Safety, Security, and Trust,

(ii) Accessibility (iii) Regulations, and (iv) Transparency:

Security and Trust

and deploy products and services that increase our clients and customer’s trust in our organization.

Accessibility

Develop and deploy products and services that are easy to use, accessible everywhere and with no barriers.

Deploy and deploy the best practices in the industry to comply with KYC, KYT, AML reporting and always be at the forefront of all regulatory requirements.

Develop and deploy the best practices in financial reporting, as well as best practices in communication of all material events for all stakeholders i.e.

and deploys products and services that are easy to use, accessible everywhere, and with no barriers.

and deploys best practices to comply with know-your-customer (“KYC”), know-your-transaction (“KYT”), and anti-money

laundering (“AML”) requirements.

best practices in financial reporting, as well as best practices in communication of all material events for all stakeholders, i.e.

customers, shareholders, suppliers, and employees.

Corporate History and Organizational Structure

ALT5 Sigma, Inc.

was formed and incorporated in the State of Delaware on March 5, 2018 under the name Buttonwood ARCA Inc.

On March 28, 2018, the Company filed a Certificate of Amendment with the State of Delaware changing our name to ALT5 Sigma.

The Company entered into a Share Exchange and Reorganization Agreement on March 21, 2018 with Société AVA Inc., a Canadian corporation, and as a result Société AVA Inc.

became a wholly owned subsidiary of the Company.

On March 28, 2018 the Company changed the name of Société AVA Inc.

to ALT5 Sigma Canada Inc.

On August 14, 2019, ALT5 Sigma Canada Inc., acquired 100% of Miningcrypt Inc., a Canadian crypto currency mining company, and on November 25, 2019, Miningcrypt Inc., changed its name to ALT5 AI Inc.

On October 31, 2020, due to a severe storm, the mining equipment suffered fatal damages and the mining operations ceased.

is intended to be used to hold intellectual properties and develop machine learning and or artificial intelligence software.

ALT5 AI Inc., does not currently have any assets and is not currently operating.

On February 21, 2020, ALT5 Sigma Canada Inc., formed a wholly owned limited liability company named ALT5 Pro LLC in the country of Saint-Vincent and the Grenadines.

On February 10, 2023, ALT5 Sigma Canada Inc., formed a wholly owned corporation in the country of Lithuania named UAB ALT5 Sigma Prudentia and have applied for a cryptocurrency exchange license with the Central Bank of Lithuania.

The application was filed and is pending approval.

On March 16, 2023, ALT5 Sigma, Inc., formed a wholly owned corporation in the State of New York, by the name of ALT5 Securities Inc.

On June 28, 2023, ALT5 Sigma Canada Inc., acquired all of the shares of a company in the Czech Republic by the name of Cypherlynx s.r.o.

Cypherlynx s.r.o.

has limited operating history and is licensed in the Czech Republic to operate a cryptocurrency exchange.

The company has filed a name change to ALT5 Sigma Prudentia s.r.o.

and the name change is pending.

On May 10, 2024, ALT5 Sigma, Inc.

History and Organizational Structure

was incorporated in the State of Delaware on March 5, 2018 under the name Buttonwood ARCA Inc.

On March 21, 2018, it entered

into a Share Exchange and Reorganization Agreement with Société AVA Inc., a Canadian corporation, and, as a result, Société

became a wholly-owned subsidiary of ALT5 Sigma.

On March 28, 2018, ALT5 Sigma, Inc,.

filed a Certificate of Amendment with the

Secretary of State of the State of Delaware changing its name from Buttonwood ARCA Inc.

to ALT5 Sigma, Inc.

Also, on March 28, 2018,

in connection with the Société AVA Inc.

transaction, the name of that entity was changed to ALT5 Sigma Canada Inc.

August 14, 2019, ALT5 Sigma Canada Inc., acquired 100% of Miningcrypt Inc., a Canadian cryptocurrency mining company, and, on November

25, 2019, Miningcrypt Inc., changed its name to ALT5 AI Inc.

On October 31, 2020, due to a severe storm, the mining equipment suffered

catastrophic damage and all mining operations ceased.

is intended to hold intellectual property and develop machine learning

and/or artificial intelligence software.

does not currently have any assets and is not currently in operation.

February 21, 2020, ALT5 Sigma Canada Inc., formed a wholly owned limited liability company named ALT5 Pro LLC in the country of Saint-Vincent

and the Grenadines.

March 16, 2023, ALT5 Sigma, Inc., formed a wholly-owned corporation in the State of New York, named ALT5 Sigma Markets Inc.

May 10, 2024, ALT5 Sigma, Inc.

was acquired by JanOne Inc.

Organizational Structure Chart

Executive Summary

ALT5 Sigma, Inc., is a financial services and Fintech holding company.

April 8, 2025, Alt5 Sigma, Inc., formed a wholly-owned corporation in the State of Wyoming, named Alt5, Inc.

On August 5, 2025, Alt5,

formed a wholly-owned corporation in the State of Wyoming, named Alt5 Digital Holdings, Inc.

Alt 5 Digital Holdings, Inc.

custodian of the Company’s WLFI tokens.

October 10, 2025, Alt5, Inc.

formed a wholly-owned corporation in the State of Wyoming named Alt 5 Sigma Digital Asset Treasury Company,

This entity has no assets or operations.

May 9, 2025, the Company acquired Fortress II Holdings Ltd.

d/b/a Mswipe.

Mswipe is a next-generation payment solutions provider offering

multi-currency, fiat payment card services, along with crypto-enabled capabilities through its existing integration with the ALT5 Subsidiary

Its suite of physical and virtual cards, available on both the Visa ® and Mastercard ® networks,

allows users to seamlessly spend traditional and digital currencies worldwide (see Note 3).

In February 2026, Mswipe changed its name

to StrataCarte.

Organizational

Structure Chart

Sigma, Inc., is a financial services and Fintech holding company.

ALT5 Sigma, Inc.

was created by financial industry specialists out of the necessity to provide the digital asset economy with the best practices of the industry and state of the art over-the-counter trading of securities.

was created by financial industry specialists to provide

the digital asset economy with the best practices of the industry and state-of-the-art over-the-counter trading of technology and services.

ALT5 Sigma, Inc., operates two distinct wholly-owned subsidiaries, ALT5 Sigma Canada Inc., and ALT5 Securities Inc.

ALT5 Sigma Canada Inc., provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and custodianship of digital assets through its wholly owned subsidiaries.

ALT5 Sigma Canada has four wholly owned subsidiaries, ALT5 AI Inc., ALT5 Pro LLC, UAB ALT5 Sigma Prudentia and ALT5 Prudentia s.r.o.

ALT5 Sigma Canada group of companies’ products and services are target at business two business (B2B) only and not a retail clientele.

The global target market for ALT5 Sigma Canada group of companies are banks, broker dealers, funds, family offices, proprietary trading firms, liquidity providers, financial information providers, and merchants.

Business Model/ Revenue Model

The Company obtains its revenue from initial installation fees or setup fees, monthly maintenance fees, spreads and transaction commissions fees.

Our products and services are marketed to banks, broker dealers, funds, family offices, proprietary trading firms, liquidity providers, financial information providers, payment processing partners and merchants.

The Company has a total of approximately 1,900 corporate clients’ customers located in 50 countries.

Product Overview

ALT5 Prime is an electronic over-the-counter trading platform, enabling registered and approved customers to buy and sell digital assets.

Customers can purchase digital assets with US dollars, Canadian dollars, Euros, and British Pounds and customers may sell digital assets and receive US dollars, Canadian dollars, Euros and British Pounds.

ALT5 Prime is available through a browser-based access, mobile phone application named ALT5 Pro that can be downloaded from the Apple store and Google Play store, or through the company’s FIX API as well as through Broadridge’s NYFIX gateway to approved customers.

Depending on their geographic location, registered and approved Customers may buy and sell a number of digital assets including, but not limited to:

Symbol Name Symbol Name Symbol Name

AAVE Aave DASH Dash SNX Synthetix

APE Apecoin DOGE Dogecoin SOL Solana

ADA Cardano DOT Polkadot SUSHI Sushiswap

ALGO Algorand ETH Ethereum TRUMP Official Trump

ATOM Cosmos FTM Fantom / Sonic TRX Tron

AU AutoCrypto HKD HongKongDao UNI Uniswap

AVAX Avalanche LINK Chainlink USDC USD Coin

BCH Bitcoin-Cash LTC Litecoin USDT Tether USD

BNB BNB MANA Decentraland UST TerraClassicUSD

BSV Bitcoin SV MATIC Polygon XLM Stellar

BTC Bitcoin MKR Maker XRP Ripple

BTCN BitcoinNote MXN Moneta Digital XTZ Tezos

COMP Compound QNT Quant YFI Yearn.finance

DAI Dai SHIB Shiba-inu

ALT5 Prime screen sample:

ALT5 Pay is a crypto currency payment gateway enabling registered and approved global merchants to accept and make crypto currency payments or integrate the payment platform into their application or operations using the plug in with WooCommerce and or the company’s checkout widgets and APIs.

Merchants have the option to automatically convert to US dollars, Canadian Dollars, Euros and/or British Pound or hold the digital assets.

ALT5 Pay screen sample:

▪ Ability to offer multiple digital assets

▪ Support 24/7

▪ Complete backend control through customizable administration dashboard.

▪ Audit trades for clients

▪ Automated trade confirmation email and customized Monthly statements

▪ Ability to place edit and cancel limit orders into order book via API

▪ Unlimited Accounts per user

▪ Accept fiat deposits (USD, CAD, EUR and GBP).

▪ Supported order types including market, limit and stop

▪ Endpoints supporting connections to trading interfaces, API, and related user-directed systems

▪ Integrated system to document customer KYC for onboarding process

▪ Connect to FIX, Binary, WebSocket, REST and custom APIs.

▪ Run reports, transactions, treasury

▪ Unlimited user profile

▪ Global setting protections in force to prevent unauthorized account activity, including unusual withdrawal requests.

▪ All platform data is replicated and backed up in real-time.

▪ Built in protection against brute force denial of service (DoS) and distributed denial of service (DDoS) attacks and active whitelist/blacklist management control.

▪ Internal Service interaction utilize separate authentication contexts and are not exposed to the Internet

▪ All website data is transmitted via encrypted transport layer security (TLS) connections (i.e.

▪ Cold Storage Wallet Management

▪ Encrypted User Information

▪ Two Factor authentication

Trading Features

▪ Multiple available views, including price chart, depth chart, order book and recent trades ticker.

▪ Live order book displays buy and sell orders with live spread calculation.

▪ Six chart styles including line, bar, area and candles.

▪ Ability to set custom chart durations ranging from one minute to years

▪ Ability to customize color and styles of bars, borders, wicks, price lines, backgrounds and grid

▪ Multiple scale styles including auto, percentage and logarithmic

▪ Ability to report block trade Integrated ability to save current chart view to jpeg

▪ 58 available indicators including linear

▪ Regression curves, moving averages and oscillators

▪ Ability to draw custom trendlines, pitchforks, and more that scales and move with chart.

Sigma Canada Inc.

provides next-generation, blockchain-powered technologies for tokenization, trading, clearing, settlement, payment,

and custodianship of digital assets through its wholly-owned subsidiaries.

ALT5 Sigma Canada has three wholly-owned subsidiaries, ALT5

AI Inc., ALT5 Pro LLC, and ALT 5 ATM Inc.

Sigma Canada group of companies’ products and services are targeted to business two business (“B2B”) customers and

not retail customers.

The global target market for ALT5 Sigma Canada group of companies are banks, broker-dealers, funds, family offices,

proprietary trading firms, liquidity providers, financial information providers, and merchants.

Model/ Revenue Model

Sigma Canada obtains its revenue from initial installation fees or setup fees, monthly maintenance fees, spreads, and transaction commissions

products and services are marketed to banks, broker-dealers, funds, family offices, proprietary trading firms, liquidity providers, financial

information providers, payment processing partners, and merchants.

Company has approximately 1,900 corporate customers located in 50 countries.

Prime is an electronic over-the-counter trading platform, enabling registered and approved customers to buy and sell digital assets.

Customers can purchase digital assets with US dollars, Canadian dollars, Euros, and British Pounds and customers may sell digital assets

and receive US dollars, Canadian dollars, Euros and British Pounds.

ALT5 Prime is available through a browser-based access, mobile phone

application named ALT5 Pro that can be downloaded from the Apple store and Google Play store, or through the company’s FIX API

as well as through Broadridge’s NYFIX gateway to approved customers.

on their geographic location, registered and approved customers may buy and sell a number of digital assets including, but not limited

HongKongDollar

TerraClassicUSD

Yearn.finance

Prime screen sample:

Pay is a cryptocurrency payment gateway enabling registered and approved global

merchants to accept and make cryptocurrency payments or integrate the payment platform into their application or operations using plugins

for WooCommerce and/or the company’s checkout widgets and APIs.

Merchants have the option to automatically convert to US dollars,

Canadian Dollars, Euros and/or British Pound.

Pay screen sample:

to offer multiple digital assets

fiat deposits (USD, CAD, EUR and GBP).

order types including market, limit and stop

backend control through customizable administration dashboard.

supporting connections to trading interfaces, API, and related user-directed systems

trades for clients

system to document customer KYC for onboarding process

trade confirmation email and customized Monthly statements

to FIX, Binary, WebSocket, REST and custom APIs.

to place edit and cancel limit orders into order book via API

reports, transactions, treasury

Accounts per user

setting protections in force to prevent unauthorized account activity, including unusual

withdrawal requests.

Service interaction utilize separate authentication contexts and are not exposed to the Internet

platform data is replicated and backed up in real-time.

website data is transmitted via encrypted transport layer security (TLS) connections (i.e.

in protection against brute force denial of service (DoS) and distributed denial of service (DDoS) attacks and active whitelist/blacklist

management control.

Storage Wallet Management

User Information

Factor authentication

available views, including price chart, depth chart, order book and recent trades ticker.

available trendlines styles including rays, angles and arrows

order book displays buy and sell orders with live spread calculation.

available pitchforks styles including pitchforks, Gann boxes, and Fibonacci’s

chart styles including line, bar, area and candles.

available brushes including ellipses, triangles and rectangles

to set custom chart durations ranging from one minute to years

available test box styles including flag marks, arrows and price labels

to customize color and styles of bars, borders, wicks, price lines, backgrounds and grid

available pattern descriptors including cypher, ABCD and Elliott formations

scale styles including auto, percentage and logarithmic

available forecasting markers including bars, ghosts, spreads and areas

to report block trade Integrated ability to save current chart view to jpeg

available icons to markup charts.

▪ Custom area measurement tool to find duration percentage change and price change Automatic calculation of fees included in order price

▪ Multiple custom user reports including trade activity, transaction activity, and treasury activity

The digital assets market for our ALT5 Prime and ALT5 Pay products and services is a relatively new industry and only a hand full of companies have emerged as recognized brands providing exchange or trading platforms such as Coinbase, Kraken, and Binance.

These platforms target the retail digital asset investors but currently account for the largest trading volume in dollar equivalent and number of coins traded.

We believe that some of the leading financial institutions license or buy the technology and services necessary to be able to be effectively and quickly provide these services to their customers and prevent the attrition of assets under management due to the movement of same to digital assets investments and whereby the ALT5 products are services are highly advantageous for these customers as they provide a best-of-breed solutions.

The Company’s products and services are designed for banks, broker dealers, funds, family offices, proprietary trading firms, liquidity providers, financial information providers, and merchants.

Our main target market and focus are FINRA-registered broker dealers and global merchants.

According to the most recent information from FINRA, there are 3,712 broker-dealers registered and under FINRA’s supervision, representing 629,112 registered representatives.

As of December 2024, the U.S.

equity markets remain the largest globally, with a market capitalization of approximately $63 trillion, accounting for over 50% of the global equity market's value ( Morningstar) .

This reflects significant growth from previous years, with the U.S.

available indicators including linear

area measurement tool to find duration percentage change and price change Automatic calculation of fees included in order price

curves, moving averages and oscillators

custom user reports including trade activity, transaction activity, and treasury activity

to draw custom trendlines, pitchforks, and more that scales and move with chart.

is a next-generation payment solutions provider offering multi-currency, fiat payment card services, along with crypto-enabled capabilities

through its existing integration with the ALT5 Subsidiary platform.

Its suite of physical and virtual cards, available on both the Visa®

and Mastercard® networks, allows users to seamlessly spend traditional and digital currencies worldwide.

digital assets market for our ALT5 Prime, ALT5 Pay, and StrataCarte products and services is a relatively new industry

and only a handful of companies have emerged as recognized brands providing retail focused exchange or trading platforms, such as Coinbase,

Gimini, Crypto.com, Kraken, and Binance.

These platforms primarily target the retail digital asset investors but currently account for

the largest trading volume in dollar equivalent and number of coins traded.

The digital assets market for our ALT5 Prime, ALT5 Pay, and StrataCarte products and services is a relatively new

industry and only a handful of companies have emerged as recognized brands providing retail focused exchange or trading platforms, such

as Coinbase, Gimini, Crypto.com, Kraken, and Binance.

These platforms primarily target the retail digital asset investors but currently

account for the largest trading volume in dollar equivalent and number of coins traded.

Our services are aimed at business-to-business

Our interface, speed, customer service and feature set are aimed at this market, enabling us to tailor our product to the B2B

market, thus providing us with a competitive advantage.

We offer a white-label product that can be seamlessly integrated with a customer’s

existing systems.

ALT5 Sigma Canada’s products and services are designed for banks, broker-dealers, funds, family offices, proprietary

trading firms, liquidity providers, financial information providers, and merchants.

main target market and focus are FINRA-registered broker dealers, banks, and global merchants.

to the most recent information from FINRA, there are 3,249 broker-dealers registered and under FINRA’s supervision, representing

approximately 628,000 registered representatives.

of December 2025, the U.S.

equity markets remain the largest globally, with a market capitalization of approximately $72 trillion, accounting

for over 50% of the global equity market’s value ( Siblis Research) .

This reflects significant growth from previous years,

with the U.S.

market adding nearly $9 trillion in value in 2025 alone.

In comparison, the global digital assets market experienced substantial growth in 2024, with its market capitalization nearly doubling to approximately $3.91 trillion by mid-December, before consolidating at $3.40 trillion ( Crowdfund Insider) .

Bitcoin continues to lead the digital assets market, maintaining a significant share of the total market capitalization.

The Company projects that 3% of assets currently allocated to U.S.

In comparison, the global digital assets market experienced substantial

growth in 2024, with its market capitalization nearly doubling to approximately $3.91 trillion by mid-December, before consolidating

at $3.0 trillion ( Coingecko) .

Bitcoin continues to lead the digital assets market, maintaining a significant share of the total

market capitalization.

ALT5 Sigma Canada projects that 3% of assets currently allocated to U.S.

equities will transition to digital assets over the next 36-to-60 months.

1 unchanged sentence

equity market capitalization of $72 trillion, this 3% shift represents approximately $2.16 trillion.

Such a reallocation could increase the global digital assets market capitalization to approximately $5.29 trillion.

Given that average trading volumes of digital assets have been around 19% of the total market capitalization, this would correspond to daily trading volumes of approximately $1.0 trillion globally and $380 billion in the U.S.

The Company further believes that retail and institutional investors will continue to seek advice, trade execution, and safekeeping of their assets, including digital assets such as Bitcoin, through their FINRA-registered broker-dealers.

Therefore, we anticipate that our main target market, FINRA broker-dealers, will aggregate 90% of the daily trading volume, representing $342 billion of daily trading volume or $124.8 trillion in annual trading volume and potential revenues of $8.64 billion.

According to a McKinsey report, the global payments industry revenue reached $2.1 trillion in 2021.

If calculated at an annualized growth rate of 9%, global payments industry revenue is projected to reach $3.3 trillion in 2026.

Specifically, the crypto payment gateway market size is expected to reach $4.12 billion by 2029, growing at a CAGR of 16.8% from $1.19 billion in 2022, according to Maximize Market Research Private Limited.

Looking ahead, the Boston Consulting Group (BCG) projects that global payments revenues will continue to grow, albeit at a moderated pace.

BCG's Global Payments Report 2023 forecasts an annual growth rate of 6.2%, with revenues expected to reach $2.2 trillion by 2027 ( BCG Global) .

Such reallocation could increase

the global digital assets market capitalization to approximately $5.16 trillion.

Worldwide average trading volume of all assets is approximately

$12-$14 trillion per day.

Given that average daily trading volumes of digital assets have been around $162 billion, the digital asset

market represents approximately 1.2% of global volume.

Global trading volume is growing at a compounded annual growth rate of approximately

9%, while digital assets trading volume is growing at a compounded annual growth rate of approximately 17%.

ALT5 Sigma Canada

further believes that retail and institutional investors will continue to seek advice, trade execution, and safekeeping of their

assets, including digital assets such as Bitcoin, through their FINRA-registered broker-dealers.

Therefore, we anticipate that our main

target market, FINRA broker-dealers, will aggregate 90% of the daily trading volume, representing $342 billion of daily trading volume

or $124.8 trillion in annual trading volume and potential revenues of $8.64 billion.

to a McKinsey report, the global payments industry revenue reached $2.5 trillion in 2025.

If calculated at an annualized growth rate

of 7%, global payments industry revenue is projected to reach $2.7 trillion in 2026.

Specifically, the crypto payment gateway market

size is expected to reach $3.5 billion by 2030, growing at a CAGR of 15.6% from $1.5 billion in 2024, according to ResearchandMarkets.com.

ahead, the Boston Consulting Group (BCG) projects that global payments revenues will continue to grow, albeit at a moderated pace.

Global Payments Report 2025 forecasts an annual growth rate of 4.0%, with revenues expected to reach $2.35 trillion by 2029 ( BCG Global) .

This adjustment reflects a combination of market dynamics and macroeconomic factors influencing the industry.

In the realm of cryptocurrency payments, the market is experiencing significant growth.

Future Market Insights projects that the crypto payment gateways market will expand from $1.29 billion in 2023 to approximately $4.85 billion by 2033, representing a compound annual growth rate (CAGR) of 14.1% ( Future Market Insights).

This growth is driven by increasing adoption of cryptocurrencies and advancements in payment technologies.

Sales and Marketing

ALT5 Sigma has outsourced a portion of its sales and business development to resellers.

It is the company’s strategy to target its primary market through conferences, tradeshows, direct mailing and other digital advertising.

The company intends on concentrating its marketing efforts in the United States and Canada as well as establish partnerships in other markets such as Europe, and Asia.

Revenue Model

ALT5 Sigma generates revenue through three main line items.

Installation or a onetime setup fee, which may vary depending on size and depth of installation.

Monthly maintenance, which may also vary depending on the size and depth of installation.

Transaction fees, which range from 0.25% to 5% on all transactions, buy and or sell or payment processing depending on industry and volume.

Historical Transaction Volume, Revenue, Profit

ALT5 Sigma, Inc., transaction volume reached a cumulative of $4.5 billion since inception and more specifically was $39.0 million in 2020, $442.0 million in 2021, $743.0 million in 2022 and has $1.1 billion in 2023 and $2.2 billion in 2024 with corresponding consolidated revenue of $12.5 million and profit of $0.7 million in revenue and $4.3 million in net loss for 2020, $3.5 million in revenue and $12.3 million in net loss for 2021, $9.1 million and $0.5 million in net profit for 2022 and $11.9 million in revenue and $3.4 million in profit for 2023.

growth is driven by increasing adoption of cryptocurrencies and advancements in payment technologies.

and Marketing

Sigma Canada has outsourced a portion of its sales and business development

to resellers.

It is our strategy to target its primary market through conferences, tradeshows, direct mailing, and other digital advertising.

ALT5 Sigma Canada intends on concentrating its marketing efforts in the United States and Canada as well as establish partnerships in

other markets such as Europe, and Asia.

Sigma Canada generates revenue through three main line items.

or a onetime setup fee, which may vary depending on size and depth of installation.

maintenance, which may also vary depending on the size and depth of installation.

fees, which range from 0.25% to 5% on all transactions, buy and or sell or payment processing

depending on industry and volume.

Transaction Volume, Revenue, Profit

Sigma Canada’s, transaction volume reached $8.0 billion cumulatively

since inception and more specifically was $39.0 million in 2020, $442.0 million in 2021, $743.0 million in 2022, $1.1 billion in 2023,

$2.2 billion in 2024, and $3.5 billion in 2025, with corresponding consolidated revenue of $12.5 million and profit of $0.7 million in

revenue and $4.3 million in net loss for 2020, $3.5 million in revenue and $12.3 million in net loss for 2021, $9.1 million and $0.5 million

in net profit for 2022, $11.9 million in revenue and $3.4 million in profit for 2023, $15.5 million in revenues and $0.6 million in profit

for 2024 and $23.5 million in revenues and $3.3 million in net loss for 2025.

Biotechnology

We are also a clinical-stage biopharmaceutical company focused on becoming the leader in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction.

JAN101 (formerly known as TV1001SR) is a potential treatment for PAD, a vascular disease that affects more than 8.5 million people in the U.S.

and more than 60 million people

We expected to commence Phase IIb/III clinical trials for the treatment of PAD in 2025.

We are also working with a novel formulation of LDN that we call JAN 123, which includes a biphasic release of the product.

The release properties of JAN123 provide for an immediate release of a portion of the product with a slow, sustained release of the remaining product.

Importantly, the rapid release of LDN has been reported to lead to vivid and lucid unpleasant dreams, which should be eliminated with the formulation of JAN123.

Initially, we expect that a single tablet of JAN123 will be administered orally, once a day before sleep, with eventual titration up to two tablets before sleep.

In the fourth quarter of our 2024 fiscal year, our board of directors determined that we would form a new subsidiary and capitalize it with JAN123 and certain of our other biopharma assets.

Accordingly, we incorporated a Nevada corporation known as Alyea Therapeutics Corporation (“Alyea”) and expect to build upon and complete the capitalization of Alyea during the first half of our current fiscal year.

In that context, our financial statements for the 2023 and 2024 fiscal years will show some, if not all, of our biopharmacy segment as a discontinued operation.

Pain is a protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses can be mounted.

The National Institutes of Health (the “NIH”) defines chronic pain as pain that persists beyond the normal healing time of an injury or that persists longer than three months.

It is estimated that chronic pain affects 100 million individuals in the United States and over 1.5 billion people worldwide;

thus, more people suffer from chronic pain than diabetes, heart disease, and cancer combined (Cowen Therapeutic Categories Outlook, March 2019).

Chronic pain exacts a tremendous cost in terms of direct treatment and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden for patients and their families.

According to an Institute of Medicine of the National Academies report, pain is a significant public health problem in the United States that costs society between $560 billion and $635 billion annually.

Despite the magnitude of the pain problem, innovation in the development of therapeutic solutions has been largely absent.

Since 2010, there have been 20 approvals by the FDA for the treatment of pain, of which 12 were opioid variants, one was an extended-release generic corticosteroid, five were variants of aspirin, and two were variants of other existing drugs.

We are developing a novel product candidate designed to overcome the limitations of current treatment options for patients with PAD who suffer from chronic pain.

According to a research study by Stanford University, more than 24% of patients with PAD are at risk of high opioid use.

By treating pain at the source and presenting patients and physicians with better and safer treatment alternatives, we expect to minimize opioids at the prescription pad.

Given the properties of JAN101, we have made the strategic decision to focus initially on pain associated with PAD by treating the underlying cause of PAD.

The NIH defines chronic pain as pain that persists either beyond the normal healing time of an injury or longer than three months.

We believe that chronic pain represents a significant public health crisis.

It is estimated that chronic pain affects 100 million individuals in the United States and over 1.5 billion people worldwide;

thus, more people suffer from chronic pain than diabetes, heart disease, and cancer combined (Cowen Therapeutic Categories Outlook, March 2019).

Chronic pain is the leading cause of long-term disability in the United States, and approximately 23 million adults in the United States experience severe pain over a three-month period.

Globally, the prevalence of chronic pain is even larger, with over one billion people worldwide affected each year.

Common types of chronic pain include those of neuropathic and inflammatory origin and may involve the skin, muscles, joints, bones, tendons, ligaments, and other soft tissues.

Chronic pain is associated with a variety of clinical conditions including, but not limited to, arthritis, spinal conditions, cancer, fibromyalgia, diabetes, surgical recovery, visceral injury, and general trauma.

Pain is a necessary protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses can be mounted.

Pain is signaled by specialized cells in the peripheral nervous system called nociceptors, or pain-sensing fibers.

These pain-sensing fibers normally transmit information about stimuli that approach or exceed harmful intensity from different locations in the body to the brain, which registers this information as a sensation of pain.

In the case of tissue injury due to trauma or infection, pain accompanies the associated inflammation, persists for the duration of the inflammatory response, and aids healing by inhibiting use of the affected body part.

Pain also can modify the central nervous system, such that the brain becomes sensitized and registers more pain with less provocation.

This is called central sensitization.

When central sensitization occurs, the nervous system goes through a process called wind-up and gets regulated in a persistent state of high reactivity.

This persistent, or up-regulated, state of

reactivity lowers the threshold for what triggers the sensation of pain and can result in the sensation of pain even after the initial injury might have healed.

When there is dysfunction in pain signaling, injury to the nervous system, or an unhealed injury, pain becomes no longer just a symptom, but a disease in itself.

Soin Therapeutics

ALT5 Sigma Corporation acquired Soin Therapeutics, a company focused on the development of a novel formulation of low-dose naltrexone (“LDN”) for the treatment of chronic regional pain syndrome (“CRPS”) in 2022.

CRPS is a rare pain disorder, characterized by a complex set of symptoms, affecting approximately 200,000 patients annually in the US.

There are currently no approved treatments for patients with CRPS.

Prior to the acquisition, Soin Therapeutics received Orphan Drug Designation for the product, which provides a variety of incentives for developing the product in this indication.

JAN123 is a novel formulation of 2.0 mg of LDN that results in a biphasic release of the product.

The release properties of JAN123 provide for an immediate release of less than half the product with a slow, sustained release of the remaining product.

Importantly, the rapid release of LDN has been reported to lead to vivid and lucid unpleasant dreams, which should be eliminated with the formulation of JAN123.

Initially, a single tablet of JAN123 will be administered orally, once a day before sleep, with eventual titration up to two tablets (4 mg) before sleep.

Naltrexone was first synthesized in 1965 and approved by the FDA for the oral treatment of opioid dependence in 1984, with the brand name Trexan.

Later it was approved for the oral treatment of alcohol dependence in 1995, when the brand name was changed by DuPont to ReVia.

A depot formulation for intramuscular injection was approved by the FDA under the brand name Vivitrol for alcohol dependence in 2006 and opioid dependence in 2010.

Typical oral doses are 50 to 100 mg daily, with a once-monthly intramuscular formulation also available.

At these doses, Naltrexone has been shown to function as a nonselective opioid antagonist with a high affinity for µ opioid receptors, which decreases addiction cravings (Schumacher, Basbaum et al.

2017, Opioid Agonists &

Clinical Pharmacology, 14e .

New York, NY, McGraw-Hill Education).

However, there is a risk that patients who are non-compliant with oral naltrexone may experience opioid intoxication simply by skipping doses of naltrexone.

Oral bioavailability is also variable from patient to patient, largely due to first-pass metabolism.

Thus, naltrexone is pharmacologically effective, but may be ineffective in a real world setting without counseling and strong patient support (Minozzi, 2011, Oral naltrexone maintenance treatment for opioid dependence.

Chchrane Database Syst Rev (4), CD001333).

There are also multiple generic Naltrexone tablets available on the market for oral administration.

Low-Dose Naltrexone (LDN)

Compared to the standard dose, LDN is defined as a daily dose of Naltrexone of 1 to 5 mg, which is 10- to 100-fold lower than the dose used to manage substance use disorders (LDN Research Trust, Toljan and Vrooman 2018, Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.

Med Sci (Basel) 6 (4)).

Off-label uses of Naltrexone at lower doses have been explored based on a different mechanism of action for the treatment of inflammatory, rheumatologic, and neurologic conditions.

These include multiple sclerosis, fibromyalgia, Crohn disease, chronic fatigue syndrome (CFS), and, more recently, CRPS.

At the low doses used for these conditions, Naltrexone is thought to act as an immune modulator.

Some speculate that this effect is related to reduced neuroinflammation in the case of disorders like CFS (Cant, Dalgleish et al.

2017, Naltrexone Inhibits IL-6 and TNFalpha Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors.

Front Immunol 8 :

Evidence suggests that, at low doses, Naltrexone antagonizes TLR4 on activated glial cells without the previously mentioned function as a mu-opioid receptor antagonist (Chopra and Cooper 2013, Treatment of Complex Regional Pain Syndrome (CRPS) using low-dose naltrexone LDN).

J Neuroimmune Pharmacol 8 (3):

TLR4 has been shown to be a key mediator of microglial activation, which has been identified as a causal mechanism of neuropathic pain in CRPS.

Microglial activation is associated with the release of pro-inflammatory cytokines, reactive oxygen species, and prostaglandins, which amplify the inflammatory response (Carniglia, Ramírez et al.

2017, Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases.

Mediators of Inflammation 2017 :

Thus, LDN presents a promising therapeutic avenue for the treatment of CRPS, a condition in which TLR4 upregulation is a

primary pathway, through attenuation of glial activation and direct targeting of TLR4 activity (Del Valle, Schwartzman et al.

2009, Spinal cord histopathological alterations in a patient with longstanding complex regional pain syndrome.

Brain Behav Immun 23 (1):

By downregulating the inflammatory cytokine release, LDN should be beneficial for CRPS patients.

CRPS patients suffer from severe debilitating pain, and even light touch or benign stimulation elicits extreme amounts of pain.

Microglial cells and glial cells oftentimes are involved in this pain-signaling pathway.

By reducing glial cell activation, Low-dose Naltrexone can treat this pain syndrome.

Another potential mechanism of action of LDN treatment on pain is a paradoxical upregulation of opioid signaling.

It is noted that, when taken at bedtime, the short-acting low-dose Naltrexone binds to receptors, which leads to a brief blockade of opioid receptors between 2 and 4 a.m.

This blockade is believed to upregulate vital life elements of the body and cause an increase in endorphin and enkephalin production.

This increase in endorphins and enkephalins will likely cause a decrease in pain that the patient experiences overall.

Therefore, LDN leads to transient opioid receptor blockade, which triggers a positive feedback mechanism that increases the production of endogenous opioids (endogenous endorphins and enkephalins) and opioid signaling (Ludwig, Zagon et al.

2017, Serum [Met(5)]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone.

Exp Biol Med (Maywood) 242 (15):

Toljan and Vrooman 2018, Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.

Med Sci (Basel) 6 (4)).

Together, these mechanisms may work to alleviate pain associated with CRPS.

Interestingly, low-dose Naltrexone also has effects on the peripheral nervous system.

In the peripheral nervous system, it was found that low-dose Naltrexone can modulate T and B lymphocyte production.

And it was noticed that low-dose Naltrexone could reduce interleukin 6, interleukin 12, and tumor necrosis factor alpha in the periphery regarding peripheral nervous systems.

CRPS patients often have an increase in inflammatory cytokines and may often note an increase in interleukin 6, 12, and tumor necrosis factor alpha.

By reducing these inflammatory cytokines back to a normal state, it is predicted that low-dose Naltrexone could treat the actual disease state of CRPS.

In summary, low-dose Naltrexone has a very specific mechanism of action that will distinctly treat CRPS through inhibition of inflammatory cytokines, glial cell activation, neuroinflammation, and increase of endogenous enkephalins and endorphins.

In other words, low-dose Naltrexone is not just treating the symptoms with this medication but also treating the underlying disease state and process specific to CRPS.

Chronic Regional Pain Syndrome (CRPS)

CRPS, also termed reflex sympathetic dystrophy (RSD), is a chronic, orphan neurologic condition that typically affects the extremities after trauma or nerve injury, and can cause severe pain.

As the most common and prominent symptom of CRPS, the pain is often deep inside the limbs with a burning, stinging, or tearing sensation.

Sensory changes are also common and may include increased sensitivity to painful stimuli, feeling pain from stimuli that are usually non-painful, and in some instances, sensory loss ( e.g.

In addition to pain, patients commonly experience an affected extremity that is warm, red, and swollen, at least initially.

As CRPS progresses, it becomes refractory to sympathetic nerve blocks, conventional analgesics, anticonvulsants, and antidepressants.

CRPS is a rare neurologic disease.

It is a painful progressive condition and is listed in the rare disease database of the National Organization for Rare Disorders (NORD).

CRPS is subdivided into two categories:

type I and type II CRPS.

In CRPS type I, there are no nerve injuries or lesions identified.

CRPS type I is also known as “reflex sympathetic dystrophy,” and it comprises about 90 percent of all cases of CRPS.

CRPS type II (causalgia), on the other hand, is diagnosed when there is evidence of nerve damage.

As described in the NORD, it was found that CRPS type I developed in 5.46 persons out of every 100,000 per year and the incidence rate of CRPS type 2 was 0.82 persons out of every 100,000 per year, giving rise to a combined incidence rate for both CRPS types I and II of 6.28 per 100,000 person-years (Sandroni, Benrud-Larson et al.

2003, Complex regional pain syndrome type I:

incidence and prevalence in Olmsted county, a population-based study.

Pain 103 (1-2):

Goh, Chidambaram et al.

2017, Complex regional pain syndrome:

a recent update.

Burns Trauma 5 :

The underlying cause of CRPS is not well understood.

In most cases, it occurs after an illness or injury that did not directly damage the nerves in the affected area (Type I).

In some cases, it occurs after a specific nerve injury (Type II).

The exact trigger of CRPS after an injury is not known, but it may be due to abnormal interactions between the central and peripheral nervous systems and/or inappropriate inflammatory responses.

There are multiple factors that may contribute to CRPS development, including immobilization, alterations to the nervous system of the body, and inflammation.

Genetic factors and psychological factors, such as anxiety, depression, and anger, may also contribute to the symptoms of CRPS.

However, there is no evidence that CRPS is a disease that can be caused by genetic factors alone, and the role of psychological factors in CRPS development remains unproven.

CRPS is treated by approaching it from different areas:

physical therapy (PT), occupational therapy (OT), medications for pain management, neuromodulation through implantable devices, and/or nerve blocks targeting the sympathetic chain.

Neridronate and zoledronate D,L-lysine monohydrate (ZLM) has been designated as an orphan drugs for the treatment of CRPS in 2013 and 2015, respectively.

However, neither of them has been approved.

Thus, there is no current FDA-approved drug for CRPS.

Clinical Studies of LDN on CRPS

LDN has been widely used for chronic pain and inflammatory condition and has been shown to alleviate symptoms of pain in patients with chronic pain.

A number of case studies have also reported positive effects for LDN in the treatment of CRPS.

Chopra et al.

reported 2 patient case studies with CRPS who experienced significantly less pain with 4.5 mg daily LDN treatment (Chopra and Cooper 2013, Treatment of Complex Regional Pain Syndrome (CRPS) using low-dose naltrexone (LDN).

J Neuroimmune Pharmacol 8 (3):

The remission of pain and dystonic spasms in Case 1, as well as remission of all CRPS symptoms (including fixed dystonia) in Case 2, provide evidence that a multi-modal interventional approach, which includes low-dose Naltrexone (a known glial attenuator), should be considered as a treatment option for the treatment of CRPS patients, particularly those patients with dystonic movement disorders.

In another CRPS case study, Sturn and Collin found alleviation of pain symptoms as early as 2 days after beginning LDN therapy, with significantly less pain at 4 weeks (Sturn and Collin 2016, Low-Dose Naltrexone:

A New Therapy Option for Complex Regional Pain Syndrome Type I Patients.

Int J Pharm Compd 20 (3):

Weinstock et al reported alleviation of pain symptoms within one month of LDN treatment, with complete remission of CRPS leg symptoms by 16 months (Weinstock, Myers et al.

2016, Identification and Treatment of New Inflammatory Triggers for Complex Regional Pain Syndrome:

Small Intestinal Bacterial Overgrowth and Obstructive Sleep Apnea.

A A Case Rep 6 (9):

In a recent case study, an CRPS patient was able to discontinue gabapentin and amitriptyline via the use of LDN, while simultaneously achieving superior pain relied (Soin, 2021, Management of pediatric complex regional pain syndrome with low-dose naltrexone.

Pain Medicine Case Reports, 5 (3), 109-113).

LDN has been reported to have benefits related to other symptoms of chronic pain syndromes as well, including dystonic spasms, CRPS flares, energy, sleep disturbances, and mood.

Systematic literature review of LDN use showed that the most commonly reported AEs with LDN use were dizziness, vomiting, nausea, and vivid dreams (Soin et al.

2021, Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome:

A Systematic Literature Review.

Pain Physician 24 (4):

Other reported AEs included headaches, abdominal pain, gastrointestinal issues, peripheral edema, restlessness, falls, somnolence, irritability, hematological abnormalities, urinary infection, difficulty concentrating, anxiety, sleepiness, hot flashes/sweating, tachycardia, depression, muscle and joint pain, fatigue, tinnitus, heartburn, dry mouth, and joint pain.

Another systematic review also evaluated occurrence of adverse events (AEs) and serious adverse events (SAEs) with LDN use and found that only mild AEs reported among the included studies (89 studies), including nausea, vomiting, and dizziness (Bolton, Hodkinson et al.

2019, Serious adverse events reported in placebo randomized controlled trials of oral naltrexone:

a systematic review and meta-analysis.

BMC Med 17 (1):

Although 119 patients reported at least one SAE in the naltrexone study arm, meta-analysis found no difference between occurrence of SAEs in naltrexone and placebo groups.

Furthermore, secondary analysis found only 6 AEs that were statistically significant:

decreased appetite, dizziness, nausea, sleepiness, sweating, and vomiting.

Efficacy of low-dose naltrexone treatment on CRPS

Author (year) Symptoms Symptoms alleviated Time to alleviation of symptoms Dose AEs and SAEs

Chopra et al (2013) swelling, allodynia, color change, temperature change, some weakness, blisters, skin ulceration, dystonic spasms, dysesthesia Dystonic spasms, CRPS flares, energy, pain tolerance, sleep disturbances, pain, mood < 2 months 4.5 mg/day None

Sturn et al (2016) Pain Pain 2 days 1.5 mg None

Weinstock et al (2016) Severe leg pain, episodic pain in arms and nose, asymmetric and shiny skin with fluctuating temperature changes, color change, edema, IBS, atypical chest pain and fatigue, edema, blue discoloration, tenderness, joint hypermobility with EDS diagnosis Leg and bowel symptoms;

all CRPS pain, bowel symptoms, and fatigue < 1 month 4.5 mg/day None

Orphan Drug Designation

An orphan disease is a rare disease affecting fewer than 200,000 people in the US.

It is often a serious or fatal condition for which there are no effective therapies.

In 1983, the Orphan Drug Act was passed to incentivize companies to develop drugs for patients with rare diseases.

Orphan drug designation provides incentives to companies, including:

• Tax credits for qualifies clinical trials

• Exemption from user fees

• Potential for seven years of market exclusivity after approval

In addition, given the small number of patients with a disease and the severity of the disease, approvals are often granted with fewer and smaller trials, saving costs and time.

JAN123 was granted Orphan Status for the treatment of CRPS.

Clinical Development Plan

LDN can be rapidly developed in the US via the 505(b)(2) regulatory pathway.

This pathway is used for candidates that contain drugs that are already approved but come in a dosage form or delivery system that is different than the original, approved product.

In this case, JAN123 fits these criteria perfectly.

LDN has the added benefit of being developed at a much lower dose (< 5 milligrams) compared to approved naltrexone products, which are 50 milligrams per tablet.

Therefore, it is likely that product development will consist of the following general steps:

• Manufacturing and approval of clinical batches of LDN tablets prior to clinical studies;

• Phase I pharmacokinetic study(ies) to confirm the release profile of LDN;

• A single Phase III study to demonstrate efficacy in CRPS.

A protocol synopsis of the development plan is presented below:

Title of study Phase I:

The Pharmacokinetincs of LDN in the fed and fasted state of a Single Oral Dose of LDN, 4 mg

Double-Blind Placebo-Controlled Trial of Low-Dose Naltrexone to Treat Complex Regional Pain Syndrome (CRPS)

Clinical Phase Phase I:

The Pharmacokinetincs of LDN in the fed and fasted state

Registration/Efficacy Study to hopefully facilitate an NDA application for the use of low-dose naltrexone to treat CRPS

To determine pharmacokinetics of single oral low-dose naltrexone in healthy participants in fasting and fed state

The primary objective is to assess the efficacy of low-dose naltrexone in treating complex regional pain syndrome symptoms (CRPS).

We plan to conduct a double-blind, randomized, placebo-controlled trial to treat CRPS using low-dose naltrexone.

For Efficacy:

1- Assess daily NRS (numerical pain scale 0 – 10) scores through the 3-month study

2- Study the possible changes or improvement in the Brief Pain Inventory (BPI) and Oswestry Disability Index (ODI) over the three-month study

We will also monitor safety labs on enrollment and termination of the study.

However, we would like to point out that this drug has been available and FDA approved at much higher doses (50 – 150mg or higher) orally with a long-standing proven safety track record.

The drug has been available with multiple different embodiments, route of administration and at much higher doses for quite a long time and the safety of the drug has already been extensively established and published.

Investigational product JAN123

Study Design Phase 1:

Single-center, dual-arm, cross-over, open-label study

Study Description

We plan to conduct a randomized, double blind placebo controlled trial to treat Complex Regional Pain Syndrome.

The study duration will be three months long.

Patients in the treatment group will receive a single tablet for the first month of a 2mg dose of Naltrexone.

Then, after 1 month, the patient will take 2 tablets for a total of 4mg for months 2 and 3.

Study conclusion will be after 3 months.

Patients in the placebo group will take a single tablet for 1 month followed by 2 tablets for month 2 and 3.

A total number of 200 patients with a 1:1 randomization will used.

Since CRPS is an orphan disease, we will likely have to use a total of 25 clinical sites or more to be able to adequately recruit the study.

Safety labs will be completed prior to first dose and upon study completion.

For clinical efficacy, we will be assessing daily NRS (1-10) pain scores, a brief pain inventory (BPI) at enrollment and at months 1, 2, and 3 (study completion) and Oswestry Disability Index (ODI) at enrollment and at months 1, 2, and 3 (study completion).

Statistically significant improvement in pain scores or any scales in the BPI or ODI are desired outcomes.

Treatment Regimen and Route of Administration Study Drugs are as follows:

Single Oral dose of JAN123, 4 mg given on separate days with and without food separated by a washout period of no less than 7 days

Patients will be dosed with either the low-dose naltrexone or placebo for three months.

Initially for the first month patients will take 1 tablet at bedtime (typically in the evenings) for the first month and then increase to 2 tablets for month 2 and 3.

Specifically the Naltrexone will be 2mg tablets, such that for the first month with the 1 tablet per day the patient will be on 2mg doses and subsequently increase to 2 tablets in the evening for a total of 4mg.

Duration of treatment:

One day for each dose.

Two doses of 2 mg each, in total, separated by a washout period of no less than 7 days.

This will be a 3 month trial or approximately 90 days.

Upon enrollment, patients will be on either low-dose naltrexone or placebo for 90 days.

Participant duration is expected to be 121 days, and at the conclusion of the study (approximately day 90 post-treatment) patients will come in for a final site visit to complete remaining surveys and within 7 days of completion the patients will obtain final safety labs which are anticipated to be a complete blood count and a comprehensive metabolic panel.

Since Naltrexone is non-opioid based and does not have withdrawal issues, patients can immediately discontinue the therapy without concerns.

As referenced earlier, the safety of Naltrexone orally is already well established and our tested doses are low.

Number of Centers Phase 1:

Single Center Clinical Trial

Multicenter Clinical Trial

Likely 25 total sites.

Keeping in mind this is an Orphan Disease state and recruitment may be quite difficult, we feel the need to have 25 clinical sites to enroll 200 patients.

Clinical sites will be likely Pain Management Centers, both academic and private practice facilities that have access to patients who suffer from CRPS and also include local PIs who have the skill set and ability to properly diagnose CRPS.

Local or regional clinical trial coordinators will be assigned to each site as well.

Enrolling participants are those who meet the diagnosis criteria of CRPS.

Typically CRPS is diagnosed using the Budapest Criteria.

Age range of 18 - 65 for enrollment, negative pregnancy test, and stable therapy for 3 months.

Adult male and female healthy subjects, 18-65 years of age, satisfying all inclusion and exclusion criteria.

Patients diagnosed with CRPS (Complex Regional Pain Syndrome), Adult male and female patients, 18-65 years of age.

Subjects Phase I:

Endpoints Phase1:

Primary Outcome Measure:

PK profile for low-dose naltrexone (Time Frame:

predose and at multiple time points after low-dose naltrexone administration).

• C max (Maximum observed plasma concentration)

• T max (Time to reach maximum plasma concentration)

• AUC 0-t (Area under the plasma concentration-time curve from 0 hour to the time of the last quantifiable concentration)

• AUC 0-inf (Area under the plasma concentration-time curve from 0 hour extrapolated to infinity)

• CL/F (Oral clearance)

Primary Outcome Measure:

Improvement in NRS pain scores over a 3-month time period.

Secondary Outcome Measure:

Improvement in Brief Pain Inventory and Oswestry Disability Index (ODI) or other verified pain scales.

End of Study will occur upon completion of the 90-day trial of the low-dose naltrexone or placebo.

It is expected that patients will complete all required surveys and testing requirements of the study.

Early termination is also a possible way to end the study due to issues such as side effects, adverse events or patient desire to withdraw from the study, among other reasons.

Assessments Standard clinical evaluation and objective measures will be employed to monitor and assess safety during the conduct of the trial.

Furthermore, the results of safety assessments will be used during the trial to monitor and protect the safety of enrolled subjects.

Strict subject and study stopping criteria will be implemented to protect the subject's well-being.

Intellectual Property

The composition of Naltrexone is off-patent and generic versions of the drug are available at 50 mg doses.

LDN has been routinely compounded in compounding pharmacies and used clinically off-label.

However, the 4.5 mg compounded tablets are associated with sleep disturbances, manifested in vivid and lucid unpleasant dreams.

For these reasons, JAN-123 was developed as a biphasic release, orally available tablet to reduce the likelihood of unpleasant dreams.

A provisional patent was filed in December 2020 and converted to a PCT application in November 2021 (Pub.

US 2022/0202807 A1).

US Patent number 11,752,143 B2 issued on September 12, 2023.

The issued claims in this patent cover the use of the biphasic LDN formulation for treatment of patients with chronic pain.

In addition, claims are made to the titration of the LDN for treating chronic pain.

While there is no guarantee that the pending applications or future pending claims will issue, the

issued US patent will provide protection of JAN123 through 2040 and the Orphan Drug Designation provides 7 years of market exclusivity after drug approval in the event that there are any challenges to this patent.

Trade Secrets and Other Proprietary Information

In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position.

For example, we have developed methods for more efficient manufacture of the biphasic LDN.

We seek to protect our proprietary information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors, and commercial partners.

Soin Purchase Agreement

On December 28, 2022, we entered into a Purchase Agreement (the “Soin Purchase Agreement”) with Soin Therapeutics, LLC.

Under the Soin Purchase Agreement, ALT5 Sigma Corporation acquired Soin Therapeutics and its LDN product, now known as JAN123.

This all- stock transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M.

The transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be issued to or transferred by Soin Therapeutics at any given time.

Tony Giordano, Ph.D.

, our Chief Scientific Officer, joined the Company in December 2019 from the Cleveland Clinic, the No.2 rated hospital in the country, where he served as Senior Director of Special Projects in the Business Development group.

Giordano has extensive experience in drug development, having served as Vice President or President of seven different biotechnology companies he co-founded, including companies developing platform technologies, a cancer vaccine, and Alzheimer’s Disease and cardiovascular therapies.

He has managed numerous clinical trials and the launch of a medical food product.

Giordano has also served as an Associate Professor and Assistant Dean of Research and Business Development at LSU Health Sciences Center in Shreveport, Louisiana (“LSU Health Shreveport”), at which he led the licensing efforts at the campus and at Abbott Labs, where, in addition to serving as a Senior Research Scientist, he was involved in technology assessment activities.

Giordano has a Ph.D.

focused in Molecular Genetics from The Ohio State University and completed Fellowships at the NIH National Cancer Institute and the NIH National Institute of Aging.

JAN101, formerly known as TV1001SR, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or PAD and treats pain.

A conclusion from a round of human studies found JAN101 prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.

In a previous study of patients with PAD, a 40 mg BID treatment with immediate release sodium nitrite led to a statistically significant reduction in reported pain, while an 80 mg BID treatment had a more pronounced effect on bioactivity and Flow Mediated Dilation, a measure of vascular function.

However, a number of subjects in both treatment groups reported headaches and dizziness following treatment.

Although this did not result in subjects discontinuing treatment, JAN101 was developed to overcome this side effect.

JAN101 was tested in a bridging study of diabetic neuropathy subjects and, during that bridging study, the subjects did not report headaches or dizziness.

Subjects in this bridging study also reported less pain following treatment and improvements in bioactivity (quantitative sensory testing, a measure of nerve function) were similar to the PAD study, where the 80 mg dosing group had the greatest improvement in Flow Mediated Dilation.

The ability to alleviate pain with BID treatment of JAN101 offers promise for a new non-addictive, non-sedating treatment of chronic pain.

Clinical Studies in Humans JAN101 Attributes

• Well-established safety profile

• Excellent bioavailability

• Lack of induced tolerance

• Non-narcotic

JAN101 does not mask pain, but instead treats the cause of pain by improving tissue and vascular function.

Benefits of Sodium Nitrite on Vascular Health

In initial research studies, sodium nitrite effectively restored ischemic tissue blood flow and was effective in a wide range of pathologies involving alterations of angiogenesis – development of new blood vessels – including diabetes, wound healing, and tissue necrosis.

Beneficial effects include enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis.

There is also a strong association between reduced circulating nitrite levels and cardiovascular diseases in humans.

We describe some of the associations and beneficial effects of sodium nitrite/nitrite below.

Plasma nitrite levels are negatively correlated to cardiovascular disease

Plasma nitrite levels were inversely related to number of cardiovascular risk factors a subject had and decreased plasma nitrite was associated with decreased flow mediated vasodilation (FMD) and increased intimal medial thickness (IMT) (both are indicators of vascular pathology).

Kleinbongard, et al.

(2006) Free Radic Biol and Medicine 40:295-302.

Plasma nitrite levels are reduced in diabetic and PAD patients

Exercise is a well-known stimulator of endothelial nitric oxide synthase activity, an enzyme that enhances nitric oxide (NO) production, which leads to increased plasma nitrite.

In the study by Allen, et al., these authors revealed that baseline plasma levels of nitrite were less in patients with diabetes mellitus (DM) or DM + PAD.

Importantly, increases in plasma nitrite levels were not observed in either DM, PAD, or DM + PAD patients after supervised exercise.

These data reveal that baseline nitrite availability is compromised in DM patients and that supervised exercise is unable to increase plasma nitrite levels but actually results in a decrease in nitrite, highlighting a physiological efficiency of this molecule.

Allen, et al., Nitric Oxide 2009 20:231-2377.

Skeletal Muscle Nitrite and Metabolite Levels are Reduced in Critical Limb Ischemia (CLI) Patients

Skeletal muscle nitrite, nitrosothiol (RSNO), nitric oxide-heme, and cGMP are all significantly reduced in CLI (the most severe form of PAD) patients.

Diabetic patients with CLI show even further nitrite reductions.

In summary, nitrite levels in various cardiovascular and vascular diseases appear to be inversely related to the severity of the disease in humans:

• Lower nitrite levels are associated with higher level of heart failure;

• Lower nitrite levels are observed in diabetic patients with PAD and are not compensated by exercise;

• Nitrite levels are lower in the muscles of patients with critical limb ischemia and are further reduced in diabetic subjects with critical limb ischemia.

Given the association between low levels of circulating nitrite and human diseases, supplementation with sodium nitrite has been studied preclinically in animals.

Below are summaries of some of the more important findings:

• Promotes angiogenesis

• Stimulates wound healing

• Prevents tissue necrosis

From Arya, et al.

Nitrite Therapy Selectively Increases Ischemic Tissue Vascular Density in a NO-dependent Manner

Chronic sodium nitrite therapy increases ischemic tissue vascular density in a NO-dependent manner.

A and B show representative images of CD31 (red) and DAPI nuclear (blue) staining from sodium nitrite and sodium nitrate ischemic gastrocnemius muscle tissue at day 7.

C and D report the vascular density of ischemic gastrocnemius muscle tissue at days

3 and 7 for 165 μg/kg sodium nitrite and nitrate treatments, respectively.

E and F demonstrate the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 from 165 μg/kg sodium nitrite plus carboxy PTIO.

(Scale bar, 150 μm.) n = 10 mice per treatment group.

Kumar D., et al., PNAS;

105:7540-7545.

Nitrite Therapy Augments Arterial Perfusion of Ischemic Tissue

Chronic sodium nitrite therapy acutely increases ischemic tissue blood flow and stimulates arteriogenesis.

A and B report 165 μg/kg sodium nitrite-induced acute changes in blood flow of chronically ischemic tissues at various time points with or without cPTIO, respectively.

C reports the number of arterial branches between PBS and nitrite therapies.

D and E illustrate vascular casting of the arterial vasculature in ischemic hind limbs of day 7 nitrite or PBS-treated mice, respectively.

*, P < 0.01 vs.

sodium nitrite.

N = 10 mice per treatment group.

Kumar D., et.al., PNAS;2008;

105:7540-7545.

Nitrite Therapy Restores Diabetic Ischemic Hind-Limb Blood Flow and Promotes Wound Heal

Unilateral femoral artery ligation was performed on 18-20 week old male Db/Db mice.

Mice were randomized to PBS or sodium nitrite (165 μg/kg) therapy twice daily via I.P.

Laser doppler flowmetry was performed at the indicated time points.

Increased wound dehiscence was noted in the PBS treated animals at day 7 but not in nitrite treated animals.

(Bir, et al., Diabetes 2014, 63(1):270-81).

Nitrite Therapy Increases Diabetic Ischemia Induced Angiogenesis

Nitrite therapy prevented ischemia mediated endothelial cell density loss in normal C57BL/6J ischemic limbs.

Nitrite therapy significantly restored endothelial cell density in ischemic limbs of diabetic mice to normal C57BL/6J levels compared to PBS therapy of non-ischemic and ischemic conditions.

These data suggest that nitrite therapy may be useful in attenuating microvascular rarefaction due to loss of nitric oxide that is observed during metabolic dysfunction (Frisbee JC AJP Integr Comp Physiol 2005 289(2):R307-16;

Stepp et al Microcirculation 2007 14(4-5):

Delayed Nitrite Therapy Restores Ischemic Hind-Limb Blood Flow

Studies were performed to determine whether nitrite mediated therapy would be effective in tissue that had been left ischemic for 5 days after femoral artery ligation.

Femoral artery ligation was performed in C57BL/6J mice and the animals

randomized to either PBS or sodium nitrite therapy 5 days after artery ligation.

Treatments were given b.i.d.

Ischemic limb blood flow was measured using laser doppler flowmetry.

(Bir, et al., Diabetes 2014, 63(1):270-81).

Delayed nitrite therapy increases SPY angiogram arteriogenesis

Delayed nitrite therapy increases SPY angiogram arteriogenesis.

Representative temporal SPY angiogram image stills (3–6s) are shown at 11 days following ligation and 6 days after beginning therapy (either PBS or sodium nitrite).

PBS control angiogram.

sodium nitrite angiogram following injection of ICG.

n = 5 animals per cohort.

Circles identify limb anatomical regions of vascular blush, whereas arrows indicate perfused vessels that progressively occur over time.

Bir, et al., Am J Physiol Heart Circ Physiol 2012;303:H178-H188.

Nitrite Therapy Prevents Tissue Necrosis in Aged Db/Db Mice

Delayed sodium nitrite (165 ug/kg) or control PBS therapy was stated 5 days post-femoral artery ligation in nine-month old Db/Db mice.

Nitrite therapy significantly prevented tissue necrosis (panel B) compared to control PBS therapy (panel A).

Panel D reports tissue necrosis severity as a function of degree of limb and digit involvement.

Nitrite therapy, but not PBS control or sodium nitrate, significantly prevented tissue necrosis.

(Bir, et al., Diabetes 2014, 63(1):270-81).

Nitrite and Hind Limb Ischemia Summary

Sodium nitrite has long been known to be a potent vasodilator (transiently increasing blood vessel diameter) that can lead to a drop in blood pressure when given acutely.

The above studies indicate that chronic administration at low doses promotes angiogenesis, unlike one-time nitrite therapy, which does not stimulate angiogenesis.

In addition, these studies and a large number of other studies not reviewed above show:

• Nitrite therapy is very specific, acting only in damaged, ischemic tissue;

• Delayed nitrite therapy effectively restores ischemic tissue blood flow;

• Nitrite therapy is effective in a wide range of pathologies involving alterations of angiogenesis including critical limb ischemia, heart failure, and tissue necrosis;

• Nitrite supplementation has had positive effects in various diabetes models, including diabetic nephropathy and diabetic wound healing;

• Beneficial effects center on enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis;

• Sustained release nitrite therapy, unlike immediate release therapy, does not lead to vasodilation or a drop in blood pressure.

JAN 101 is designed to treat diseases associated with poor vascular function.

The following table summarizes our current product candidate:

According to a research study by Stanford University, more than 24% of patients with PAD are at risk of high opioid use.

By treating pain at the source and presenting patients and physicians with better and safer treatment alternatives, we expect to minimize opioids at the prescription pad.

Peripheral artery disease

Peripheral artery disease (“PAD”) is a general term for conditions in which arterial blood flow to the limbs is partially blocked.

When there is less blood present in the extremities relative to demand, muscle pain and fatigue result, especially in the calf, which is also known as “intermittent claudication.” In many patients, pain and fatigue are relieved through rest.

Roughly half of patients with PAD are asymptomatic.

The most common cause of PAD / intermittent claudication is atherosclerosis.

Diabetes, chronic kidney disease, hypertension, and smoking are all risk factors that can increase the likelihood of PAD.

In atherosclerosis, fat deposits (plaques) build up along arterial walls, resulting in a reduction in blood flow in the legs.

This same process can cause strokes if the arteries leading up to the brain are affected.

Because of the high rate of asymptomatic patients, prevalence figures vary widely.

Some estimate that up to 200 million people worldwide have PAD, ranging from asymptomatic disease to severe.

Prevalence increases as a function of patient age, rising sharply after the age of 60.

Thus, in countries with an aging population, it is expected that the prevalence of PAD will only increase.

There is also a strong ethnic and racial component to PAD prevalence, which may be due to cultural differences in diet and exercise, along with genetic differences.

Some suggest a prevalence of eight to 12 million in the United States alone, with roughly one-third experiencing pain when walking, which improves upon resting.

The diagnosis of PAD usually begins with patient complaints of pain in the extremities.

If the patient is already being treated or monitored for diabetes or other risk factors, then the physician will check for a weak or absent pulse in the extremity.

Decreased blood pressure, poor wound healing, and whooshing sounds (via stethoscope) in the legs are also tell-tale signs of PAD / intermittent claudication.

Angiograms, electrocardiograms, and ultrasounds can also be used to image and confirm the diagnosis.

Ethnic-specific prevalence of PAD in men in the US, by age.

NHW = Non-Hispanic Whites,

AA = African American, HS = Hispanics, AS = Asian Americans, AI = American Indians.

(Criqui, 2015)

The non-drug treatment of PAD / intermittent claudication may be divided into four general categories:

• Lifestyle – Primarily changes in diet and smoking cessation.

• Exercise – Patients who walk, cycle, stretch, or swim can experience marked improvement.

Formal programs involving treadmills and track walking (usually three to five times per week) are frequently provided to patients.

However, if the pain is triggered by exercise (claudication) and is significant, it can discourage the patient from exercise.

• Angioplasty – A procedure by which the affected artery is stretched with a balloon-like device.

This procedure has limited effectiveness and is reserved for severely blocked arteries.

• Bypass Surgery – Arteries that are beyond angioplasty can be bypassed entirely.

This procedure is typically reserved for cases where the blockage is considered very long (~10 centimeters) and nearly complete.

The underlying condition is not addressed by surgery.

Surgical approaches will not, in the long run, improve exercise capacity and walking distance.

Only exercise itself, coupled with lifestyle changes and drug approaches, has this benefit.

Prescription drugs for the treatment of the underlying PAD may be divided into multiple categories, depending on the underlying condition and severity:

• Cholesterol-Lowering Agents – Statins and bile acid sequestrants.

• Antiplatelet Medications – Aspirin and related drugs, such as clopidogrel.

Cilostazol also has antiplatelet properties.

• Antihypertensives – Patients with underlying high blood pressure can and will receive any number of medications to reduce blood pressure, such as ACE inhibitors and diuretics.

• Diabetes Therapies – While a substantial portion of PAD patients may have pre-diabetes or fulminant diabetes, it is unknown if aggressive treatment of diabetes has a positive effect on PAD.

• Pain – To our knowledge, no drugs are specifically indicated for PAD-associated pain.

Pentoxifylline, for example, is indicated “…for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs.” (Sanofi-Aventis U.S.

However, the evidence supporting the effectiveness of pentoxifylline is mixed.

Short-term courses of NSAIDs, such as ibuprofen, may be used, provided the patient is not on another anticoagulant, like aspirin.

Non-drug pain relievers, such as TENS and massage therapy, may also be used in these patients.

Opioids may also be used, which creates a risk for addiction and potential misuse at the medicine cabinet by family members.

The lack of any truly effective treatment of PAD, along with encouraging early trial results using JAN101 on both improving vascular function and reducing pain in PAD patients, has created an opportunity potentially to treat this large unmet medical need.

By improving vascular function, JAN101 has the potential to reduce associated pain and improve PAD patients’ quality of life.

Our focus is to develop and commercialize novel, non-opioid, and non-addictive therapies to address, safely and effectively, the significant unmet medical need of chronic pain or treat conditions that cause pain.

The principal elements of our strategy to achieve this mission are the following:

• License, acquire, develop, and create novel, non-opioid and non-addictive therapies by leveraging our understanding of pain biology to address the large and growing problem of pain.

While innovation in medical sciences has led to exciting new treatment options in many disease areas, pain has seen limited innovation in recent years.

We have a deep understanding of the pathophysiology of pain and diseases that cause pain.

We intend to leverage this understanding to bring innovation in the pain treatment paradigm through targeted acquisitions of companies or assets in development.

Our advisors and doctors have years of collective experience in leadership positions at institutions and substantial scientific experience and understand the complexity of designing and executing clinical trials for and developing therapies.

• Leverage our management team background and expertise.

We have assembled a team with extensive experience described above.

Current Therapeutic Approaches to Treating Chronic Pain and Their Limitations

Some of the most widely used therapies to treat chronic inflammatory pain are non-steroidal anti-inflammatory drugs (“NSAIDs”).

NSAIDs can have significant side effects that include gastrointestinal bleeding, gastritis, high blood pressure, fluid retention, kidney problems, heart problems, and rashes.

On April 7, 2005, the FDA announced a decision to require boxed warnings of potential cardiovascular risk for all NSAIDs.

Corticosteroids

Corticosteroids, or steroids, also possess anti-inflammatory properties and are commonly used in the practice of pain management, either systemically or locally, depending on the condition.

Steroids work by decreasing inflammation and reducing the activity of the immune system.

While steroids are commonly used, they may have numerous and serious side effects.

These side effects may include allergic or hypersensitivity reactions, increased risk for infection, adrenal insufficiency, diabetes or decreased glucose tolerance, hypertension, loss of bone density, and loss of joint cartilage volume.

In addition, steroids should not be administered when there is an infection present because steroids can inhibit the body’s natural infection-fighting immune response.

Also, if a joint is already damaged or is subject to chronic deterioration, intra-articular, or IA steroid injections are not likely to provide any long-term restorative benefit.

For the above reasons, IA steroid injections are generally recommended to be administered no more often than every six weeks and not more than three to four times per year.

Opioids are some of the most widely prescribed therapeutics for chronic and acute pain, and sales of these drugs have quadrupled between 1999 and 2010.

According to a National Survey on Drug Use and Health report, in 2016 more than one-third of adult Americans were prescribed opioids and 230 million opioid prescriptions were written that year in the United States.

Opioids act by binding to specific receptors located on neurons in both the central and peripheral nervous system throughout the body including in the brain, spinal cord, and other nervous tissue.

Although they can be effective in providing pain relief, the increased medical use of opioids has been accompanied by an increase in the abuse and misuse of prescription opioids.

In addition, for most patients, chronic opioid use is a poor option due to an intolerance to the many side effects, including nausea, vomiting, drowsiness, and constipation, and the propensity for opioids to become less effective with long-term use.

According to the Centers for Disease Control and Prevention (the “CDC”), almost two million individuals abused or were dependent on prescription opioids in 2014.

CDC figures show that the number of opioid-related overdose deaths has quadrupled between 1999 and 2010, and currently approximately 40% of opioid overdose deaths in the United States involve a prescription opioid.

This increase in prescription opioid-related deaths in the United States prompted former President Trump to declare the opioid crisis a national Public Health Emergency in October

Opioid abuse has become an epidemic in the United States, ranking as the nation’s second most prevalent illegal drug problem.

These major issues create the need to find new approaches to treating chronic pain.

Our Approach to Treating PAD and Chronic Pain

The unmet medical need for treating PAD and chronic pain reflects the historic failure to develop novel classes of analgesics with comparable or greater efficacy, an acceptable level of adverse effects and a lower abuse liability than those currently available.

Some of the reasons for this include the heterogeneity of chronic pain and its related conditions, and the complexity and diversity of the underlying pathophysiological mechanisms for pain.

However, recent advances in the understanding of the neurobiology of pain are beginning to offer opportunities to identify new drug targets and develop new therapeutic strategies.

We have taken an innovative and targeted approach to identifying treatments for chronic pain that leverages our understanding of the pathophysiology of pain.

Pain is variable.

For example, it can be inflammatory or neuropathic in nature, and it may be localized to a specific area of the body or it may be generalized throughout.

We believe that the most effective way to treat chronic pain is through therapies that specifically target the origin of the pain signal.

We strive to maximize JAN 101’s potential based on its unique mechanism of action related to the origin of the pain signal.

A Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic Neuropathy

Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.

To evaluate the safety and efficacy of 40 and 80 mg, BID, of an oral sustained-release formulation of sodium nitrite (SR-nitrite) in patients suffering from diabetic neuropathy, and to determine whether SR-nitrite would reduce the frequency of headaches reported previously by subjects receiving the same doses of an immediate release formulation.

Study Design:

Phase II, single-center, randomized, double-blind, placebo-controlled clinical trial.

The Ohio Pain Clinic and Kettering Medical Center.

Twenty-four patients were randomized to 40 mg or 80 mg SR-nitrite or placebo twice daily for 12 weeks.

The primary objective was to determine whether headaches would be reduced using SR-nitrite.

The primary efficacy endpoint was the mean difference in the change of the Neuropathic Pain Symptom Inventory (NPSI) pain score from baseline to that reported after 12 weeks of treatment.

Secondary endpoints included changes from baseline for the Brief Pain Inventory (BPI) Scale, the RAND 36 questionnaire, Short-Form McGill Questionnaire, daily patient reported score for neuropathic pain, changes in HbA1c, PulseOx, and quantitative sensory testing.

The number of subjects reporting adverse events and the number of adverse events did not change with dose.

There were no reports of treatment-related headaches.

Although no significant differences were identified in patient responses to the questionnaires, a trend was observed.

In the NPSI assessment, patients in the 40 mg and 80 mg dosing groups reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.

A trend was also observed with the BPI total severity score.

However, the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores, where the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.

Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.

No changes were observed in HbA1c levels or PulseOx.

Small sample size.

Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.

In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain.

Similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.

The 80 mg BID treatment had the more pronounced effect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dosing group had the greatest improvement in Flow Mediated Dilation .

The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.

JAN101—Regulatory Strategy

Sodium nitrite has been previously approved as one of the active components of cyanide poisoning antidote.

This means the approval path for JAN101 is likely through a 505(b)(2) (“NDA”).

JAN101—Commercial Strategy

We currently intend to use third-party providers and manufacturers to support the commercialization JAN101, if we are successful in obtaining FDA approval.

We believe that we can promote JAN101 to the patients suffering from PAD in a cost effective manner.

We anticipate our commercial operation will include outside sales management, outside sales support, distribution support, and an internal marketing group.

Additional requisite capabilities will include focused management of key accounts, such as managed-care organizations, group purchasing organizations, and government accounts.

We intend selectively to partner with third parties with vast experience in the space, as we have been partnering for every aspect of development.

The biotechnology and pharmaceutical industries are characterized by extensive research and development efforts, rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products.

We are currently focused on the development and commercialization of our asset pipeline of novel, non-opioid, and non-addictive therapies for PAD.

The number of patients suffering from chronic PAD is large and growing.

While we believe that JAN 101 and our Chief Scientific Officer’s development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including pharmaceutical, biotechnology, and specialty pharmaceutical companies that market or develop therapeutics to treat chronic pain.

Academic research institutions, governmental agencies, as well as public and private institutions are also potential sources of competitive products and technologies.

Our competitors may have significantly greater financial resources, robust drug pipelines, established presence in the market, and expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do.

These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing, and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

The key competitive factors affecting the success of JAN 101 (as well as other subsequent product candidates), if and when approved, is likely to be its efficacy, durability, safety, price, and the availability of reimbursement from government and other third-party payors.

Significant competition exists in the PAD pain field.

Although we believe our approach to developing novel treatments for pain is unique from most other existing or investigational therapies, such as NSAIDs, corticosteroids, and opioids, we will need to compete with all currently available and future therapies within the indications where our development is focused.

With respect to JAN101, the main classes of marketed products that are available for the treatment of PAD pain include NSAIDs and opioids.

Furthermore, numerous monoclonal antibodies targeting nerve growth factor, or NGF inhibitors, are in clinical development, including two product candidates in Phase III.

There are a number of companies developing or marketing therapies for the treatment and management of pain that may compete with JAN 101, including many major pharmaceutical and biotechnology companies.

Intellectual Property

Our success depends in large part upon our ability to obtain and maintain proprietary protection for our products and technologies, and to operate without infringing or otherwise violating the proprietary rights of others.

We endeavor to protect our products using a combination of intellectual property protections and available government regulatory and marketing exclusivities afforded to new medicines.

For example, we endeavor to protect our products by, among other methods, filing United States and foreign patent applications related to our proprietary technology, inventions, and improvements that are important to the development and implementation of our business.

We also use other forms of protection, such as confidential information, trade secrets, and know-how, and trademarks to protect our intellectual property, particularly where we do not believe patent protection is appropriate or obtainable.

The proprietary nature of, and protection for, JAN 101, processes, and know-how are important to our business.

Our policy is to pursue, maintain, and defend intellectual property rights, and to protect the technology, inventions, and improvements that are commercially important to our business.

Trade Secrets and Other Proprietary Information

In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position.

For example, we have developed methods for more efficient manufacture of sustained released sodium nitrite tablets.

to protect our proprietary information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors, and commercial partners.

License Agreement

On November 19, 2019, we entered into a Patent and Know How License Agreement (the “License Agreement”) with UAB Research Foundation (“UABRF”), TheraPAD, and the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting on behalf of LSU Health Shreveport, together with UABRF and TheraPAD collectively, the “Licensors”).

Under the License Agreement, the Licensors have agreed to grant to ALT5 Sigma Corporation an exclusive, worldwide license, including the right to sublicense, to the Licensors’ patent rights and know-how related to the Licensors’ sustained release formulation of sodium nitrite.

Under the License Agreement, we have agreed to pay a non-refundable upfront license fee and certain milestone payments upon the achievement of certain milestones of up to approximately $6.5 million and certain royalty payments and annual license maintenance fees.

The License Agreement requires us to use commercially reasonable efforts to develop and commercialize JAN101.

Commercial Operations

We currently do not have any marketing and sales organization dedicated to the Biotechnology segment.

We have retained global rights to JAN-101 and JAN123, and, if either of them or one of our potential subsequent product candidates is approved by the FDA to market in the United States, we expect that our sales force will be supported by sales management, internal sales support, an outside marketing group, and distribution support.

We intend to invest in our commercial capabilities prudently by focusing our marketing efforts on the physician subspecialties that treat patients.

These physicians include, but are not limited to, pain management specialists, rheumatologist, surgeons, and sports medicine physicians.

We will also evaluate licensing and partnering with third parties to help us reach other sales channels and geographic markets inside and outside of the United States.

Government Regulation

The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs, such as those we are developing.

These agencies, and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling, and export and import of product candidates.

Government Regulation of Drug Products

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the “FDCA”) and its implementing regulations.

The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources.

Failure to comply with the applicable United States requirements at any time during the product development process, the approval process, or thereafter, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA’s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.

The process required by the FDA before a drug may be marketed in the United States generally involves the following:

• completion of pre-clinical laboratory tests, animal studies, and formulation studies in compliance with the FDA’s good laboratory practice (“GLP”), regulations;

• submission to the FDA of an Investigational New Drug Application (“IND”), which must become effective before human clinical trials may begin;

• approval by an institutional research board (“IRB”) at each clinical site before each trial may be initiated;

• performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (“GCP”) requirements to establish the safety and efficacy of the proposed drug product for each indication;

• submission to the FDA of a new drug application (NDA);

• satisfactory completion of an FDA advisory committee review, if applicable;

• satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices (“cGMP”) requirements and to assure that the facilities, methods, and controls are adequate to preserve the drug’s identity, strength, quality, and purity;

• satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;

• payment of user fees and securing FDA and approval of the NDA;

• compliance with any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy (“REMS”), and the potential requirement to conduct post-approval studies.

Pre-clinical Studies

Pre-clinical studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential safety and efficacy.

An IND sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical data, and any available clinical data or literature, among other things, to the FDA as part of an IND.

Some pre-clinical testing may continue even after the IND is submitted.

An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold.

In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.

As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.

Clinical holds also may be imposed by the FDA at any time before or during clinical trials, due to safety concerns about on-going or proposed clinical trials, or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.

Through the 505(b)2 regulatory path, the FDA allows a sponsor to rely on well documented, published studies to support the clinical development of the product.

The FDA has indicated that it will accept published data in support of the Company’s development program for JAN101 but prior to filing an NDA would require the Company to complete developmental and reproductive toxicology studies.

Clinical Trials

Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial.

Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated.

A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.

In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution.

Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their www.clinicaltrials.gov website.

The information contained in, or accessible through, this website does not constitute a part of this Annual Report.

We have included this website address solely as an inactive, textual reference.

Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:

The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, and excretion and, if possible, to gain an early indication of its effectiveness.

The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to evaluate the efficacy of the product for specific targeted diseases preliminarily, and to determine dosage tolerance and optimal dosage.

The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate sufficient data statistically to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.

Post-approval trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval.

These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication.

In certain instances, the FDA may mandate the performance of Phase IV clinical trials as a condition of approval of an NDA.

The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk.

Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients.

In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee.

Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.

During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points.

These points may be prior to submission of an IND, at the end of Phase II, and before an NDA is submitted.

Meetings at other times may be requested.

These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development.

Sponsors typically use the meetings at the end of the Phase II clinical trial to discuss Phase II clinical results and present plans for the pivotal Phase III clinical trials that they believe will support approval of the new drug.

ALT5 Sigma Corporation submitted briefing materials in 2021 describing the previous research and development activities and planned clinical trials.

Concurrently with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.

The manufacturing process must be capable of consistently producing quality batches of product candidates and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug.

In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

While the IND is active and before approval, progress reports summarizing the results of the clinical trials and non-clinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.

United States Review and Approval Process

The results of product development, pre-clinical, and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product.

The submission of an NDA is subject to the payment of substantial user fees;

a waiver of such fees may be obtained under certain limited circumstances.

The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product’s identity, strength, quality and purity.

Under the Prescription Drug User Fee Act (the “PDUFA”), guidelines that are currently in effect, the FDA has a goal of 10 months from the date of “filing” of a standard NDA for a new molecular entity to review and act on the submission.

This review typically takes 12 months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a “filing” decision after the application is submitted.

The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review.

The FDA may request additional information rather than accept an NDA for filing.

In this event, the NDA must be resubmitted with the additional information.

The resubmitted application also is subject to review before the FDA accepts it for filing.

The FDA may refer an application for a novel drug to an advisory committee.

An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions.

The FDA is not bound by the recommendations of an advisory committee;

but, it considers such recommendations carefully when making decisions.

Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured.

The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.

Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.

After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter.

An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications.

A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form.

A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional Phase III trial or other significant and time-consuming requirements related to clinical trials, non-clinical studies, or manufacturing.

If a Complete Response Letter is issued, the sponsor must resubmit the NDA that addresses all of the deficiencies identified in the letter, or withdraw the application.

Even if such additional data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.

If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product.

In addition, the FDA may require a sponsor to conduct Phase IV clinical testing, which involves clinical trials designed to assess a drug’s safety and effectiveness further after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products that already have been commercialized.

The FDA may also place other conditions on approval, including the requirement for REMS, to assure the safe use of the drug.

If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS.

The FDA will not approve the NDA without an approved REMS, if required.

A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools.

Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription, or dispensing of products.

Marketing approval may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.

The Food and Drug Administration Safety and Innovation Act (the “FDASIA”) made permanent the Pediatric Research Equity Act (the “PREA”), which requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration.

Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver.

The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective.

The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations.

A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin.

The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.

Special FDA Expedited Review and Approval Programs

The FDA has various programs, including Fast Track Designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs.

The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.

To be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need.

The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors.

The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.

The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.

A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of 10 months under current PDUFA guidelines.

Under the new PDUFA agreement, these six- and 10-month review periods are measured from the “filing” date, rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission.

Most products that are eligible for Fast Track Designation are also likely to be considered appropriate to receive a priority review.

In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials that establish that the drug product has an effect (i) on a surrogate endpoint that is reasonably likely to predict clinical benefit or (ii) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, including taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.

As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.

Moreover, under the provisions of the FDASIA, a sponsor can request designation of a product candidate as a “breakthrough therapy.” A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.

Drugs designated as breakthrough therapies are also eligible for accelerated approval.

The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.

Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

We may explore some of these opportunities for our initial (or subsequent) product candidates, as appropriate.

Post-Approval Requirements

Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product.

After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval.

There also are continuing, annual user program fee requirements for any marketed products.

The FDA may impose a number of post-approval requirements as a condition of approval of an NDA.

For example, the FDA may require post-marketing testing, including Phase IV clinical trials, and surveillance to assess further and monitor the product’s safety and effectiveness after commercialization.

In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements.

Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented.

FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use.

Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.

Once an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.

Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information;

imposition of post-market studies or clinical trials to assess new safety risks;

or imposition of distribution or other restrictions under a REMS program.

Other potential consequences include, among other things:

• restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

• fines, warning letters or holds on post-approval clinical trials;

• refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;

• product seizure or detention, or refusal to permit the import or export of products;

• injunctions or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market.

Drugs or devices may be promoted only for the approved indications and in accordance with the provisions of the approved label.

The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have promoted off-label uses improperly may be subject to significant liability.

The Hatch-Waxman Amendments

The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, added two pathways for FDA drug approval.

First, the Hatch-Waxman amendments to the FDCA authorized the FDA to approve an alternative type of NDA under Section 505(b)(2) of the FDCA.

Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials not conducted by or for the applicant and for which the applicant has not obtained a right of reference from the data owner.

The applicant may rely upon the FDA’s findings of safety and efficacy for an approved product that acts as the “listed drug.” The FDA may also require 505(b)(2) applicants to perform additional studies or measurements to support the change from the listed drug.

The FDA may then approve a new product candidate for all, or some, of the label indications for which the branded reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.

Second, the Hatch-Waxman amendments to the FDCA also established a statutory procedure for submission and FDA review and approval of abbreviated new drug applications (“ANDAs”) for generic versions of branded drugs previously approved by the FDA (such previously approved drugs are referred to as “listed drugs”).

An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications, and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures.

Premarket applications for generic drugs are termed abbreviated because they generally do not include pre-clinical and clinical data to demonstrate safety and effectiveness.

However, a generic manufacturer is typically required to conduct bioequivalence studies of its test product against the listed drug.

The bioequivalence studies for orally administered, systemically available drug products assess the rate and extent to which the active pharmaceutical ingredient (the “API”) is absorbed into the bloodstream from the drug product and becomes available at the site of action.

Bioequivalence is established when there is an absence of a significant difference in the rate and extent for absorption of the generic product and the listed drug.

For some drugs, other means of demonstrating bioequivalence may be required by the FDA, especially where rate and/or extent of absorption are difficult or impossible to measure.

The FDA will approve the generic product as suitable for an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the innovator product.

A product is not eligible for ANDA approval if the FDA determines that it is not bioequivalent to the referenced innovator drug, if it is intended for a different use, or if it is not subject to an approved Suitability Petition.

In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant’s product.

Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the Orange Book.

Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA that references a drug listed in the Orange Book must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA;

(2) such patent has expired;

(3) the date on which such patent expires;

or (4) such patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted.

This last certification is known as a paragraph IV certification.

A notice of the paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA or 505(b)(2) application refers.

The applicant may also elect to submit a “section viii” statement certifying that its proposed label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent.

If the referenced NDA holder and patent owners assert a patent challenge directed to one of the Orange Book-listed patents within 45 days of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30 months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the applicant.

The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded reference drug has expired.

Marketing Exclusivity

Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications.

The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity.

A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance.

During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or a NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval.

However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.

The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug.

This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use.

Five-year and three-year exclusivity will not delay the submission or approval of a full NDA.

However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Pediatric exclusivity is another type of marketing exclusivity available in the United States.

Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA.

The issuance of a written request does not require the sponsor to undertake the described clinical trials.

In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.

United States Coverage and Reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of any therapeutic product candidate for which we may seek regulatory approval.

Sales in the United States will depend in part on the availability of adequate financial coverage and reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE, and the Veterans Administration, as well as managed care organizations and private health insurers.

Prices at which we or our customers seek reimbursement for our initial or subsequent therapeutic product candidates can be subject to challenge, reduction, or denial by payors.

The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product.

A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available.

Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy.

In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals.

Third-party payors may not consider our initial or subsequent product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.

Healthcare Reform

In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug product candidates, restrict or regulate post-approval activities, and affect the profitable sale of drug product candidates.

Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality, and/or expanding access.

In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

In March 2010, the Affordable Care Act, formally known as the Patient Protection and Affordable Care Act (the “ACA”), was enacted by Congress and signed into law by the President.

It substantially changed the methods by which healthcare is financed by both the government and private insurers, and significantly impacted the

United States pharmaceutical industry.

The ACA, among other things:

(i) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid-managed care organizations;

(ii) established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;

(iii) expanded the availability of lower pricing under the 340B drug pricing program by adding new entities to the program;

(iv) increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;

(v) expanded the eligibility criteria for Medicaid programs;

(vi) created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;

and (vii) established a Center for Medicare & Medicaid Innovation to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drugs.

Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA.

While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law.

The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate.” Additionally, on January 22, 2018, former President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called “Cadillac” tax on certain high-cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices.

Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of two percent per fiscal year and reduced payments to several types of Medicare providers.

Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.

At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

United States Healthcare Fraud and Abuse Laws and Compliance Requirements

Federal and state healthcare laws and regulations restrict business practices in the pharmaceutical industry.

The United States laws that may affect our ability to operate include:

• the federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;

• the federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;

• HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;

• HIPAA, as amended by the federal Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;

• the federal Physician Payments Sunshine Act, which among other things, requires certain manufacturers of drugs, devices, and biologics that are reimbursable by a federal healthcare program to report annually to the United States Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members;

• similar federal laws and state law equivalents of each of the above federal laws.

Regulation Outside of the United States

To the extent that our initial or subsequent product candidates, if and when approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.

In order to market our future products in the European Economic Area (the “EEA”) and many other foreign jurisdictions, we must obtain separate regulatory approvals.

More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (an “MA”).

There are two types of Marketing Authorizations:

• the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency (the “EMA”) and which is valid throughout the entire territory of the EEA.

The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced therapy products, and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes, and auto-immune and viral diseases.

The Centralized Procedure is optional for products that contain a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific, or technical innovation or that are in the interest of public health in the EU;

• National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure.

Where a product has already been authorized for marketing in a Member State of the EEA, a National MA can be recognized in another Member State through the Mutual Recognition Procedure.

If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.

Under the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.

Data and Marketing Exclusivity

In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization.

The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU.

The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU.

The 10-year market exclusivity period can be extended to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications that, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.

In Japan, medicinal products approved for administration to a patient via a new route of administration qualify for six years of market exclusivity.

Clinical Trials

Clinical trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization (the “ICH”) guidelines on GCPs.

Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products.

If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative.

The sponsor must purchase a clinical trial insurance policy and, in most EU countries, the sponsor is liable to provide “no fault” compensation to any study subject injured in the clinical trial.

Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion from an IEC.

The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier that contains information about the manufacture and

quality of the medicinal product under investigation.

Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member State in which the trial will be conducted.

Under the new Clinical Trials Regulation (Regulation (EU) No 536/2014), which took effect on January 31, 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement.

Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees.

Medicines used in clinical trials must be manufactured in accordance with cGMP.

Other national and European Union-wide regulatory requirements also apply.

Recycling Segment - Discontinued Operations

Our wholly-owned Recycling Subsidiaries in our Recycling segment included ARCA Recycling and ARCA Canada, which recycle major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs, and Connexx, which provides call center services for the recycling segment.

The ARCA business was disposed of on March 8, 2023.

The business started in 1976 as a used appliance retailer that reconditioned old appliances to sell in their stores.

Any old appliances that could not be sold in ARCA stores were sold to scrap metal processors.

In the late 1980s, stricter environmental regulations began to affect the disposal of unwanted appliances and ARCA was no longer able to take appliances that contained hazardous components to scrap metal processors.

At that time, ARCA began to develop systems and equipment to remove the harmful materials so that metal processors would accept the appliance shells for processing.

ARCA then offered their services for disposing of appliances in an environmentally sound manner to appliance manufacturers and retailers, waste hauling companies, rental property managers, local governments, and the public.

In 1989, ARCA began contracting with electric utility companies to provide turnkey appliance recycling services to support their energy conservation efforts.

Since that time, through March 8, 2023, ARCA provided services to approximately 400 utilities and other providers of energy efficiency programs throughout North America.

Through March 8, 2023, when we disposed of our recycling business, we had contracts to recycle, or to replace and recycle, major household appliances for approximately 100 utilities and other providers of energy efficiency services across North America.

ARCA operated 17 recycling centers in the United States and Canada to process and recycle old appliances according to all federal, state, provincial, and local rules and regulations.

We used United States Environmental Protection Agency (the “EPA”) Responsible Appliance Disposal (“RAD”) Program-compliant methods to remove and manage hazardous components and materials properly, including CFC refrigerants, mercury, polyurethane foam insulation, and recyclable materials, such as ferrous and nonferrous metals, plastics, and glass.

During our operations of the recycling business, all of our facilities complied with licensing and permitting requirements, and employees who process appliances receive extensive safety and hazardous materials training.

Disposition of our Recycling Business

On March 19, 2023, the Company entered into a Stock Purchase Agreement (the “Recycling Purchase Agreement”) with VM7 Corporation (“VM7”), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting of:

(a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx.

The principal of VM7 is Virland A.

Johnson, our Chief Financial Officer.

The sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement (the “Disposition Transaction”) was consummated simultaneously with the execution of the Recycling Purchase Agreement.

Our Board of Directors unanimously approved the Recycling Purchase Agreement and the Disposition Transaction.

The economic aspects of the Disposition Transaction are:

(i) we reduced the liabilities on our consolidated balance sheets by approximately $17.6 million (excluding those related to the California Business Fee and Tax Division, as discussed below);

(ii) we will receive not less than $24.0 million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling Subsidiaries’ future performance;

and (iii) during the next five years, we may request that VM7 prepay aggregate monthly payments in the aggregate amount of $1 million.

We also received one thousand dollars for the equity of each of the Recycling Subsidiaries at the closing.

Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows:

(i) 5% of the Recycling Subsidiaries’ aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Recycling Subsidiaries’ aggregate gross revenues between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Recycling Subsidiaries aggregate gross revenues over $3,000,000 for the relevant month.

VM7 will receive credit toward the payment of the first monthly payment

(March of 2023) for any payments, distributions, or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 19, 2023.

VM7 may prepay, at any time and in total, the estimated aggregate of the future monthly payments.

That amount will be an amount equal to the then-present value of the estimated future monthly payments, discounted at the rate of 5% per annum (the “Prepayment Price”).

Furthermore, VM7 will be required to pay the Prepayment Price upon the earliest of (i) Mr.

Johnson holding less than 75% of the capital stock of VM7, (ii) VM7 selling substantially all of its assets, (iii) VM7 holding less than 50% of the capital stock of the Recycling Subsidiaries, or (iv) the Recycling Subsidiaries selling substantially all of their respective assets.

Upon payment of the Prepayment Price, VM7 will have no further purchase price payment obligations to the Company.

Additional terms of the Disposition Transaction are:

(i) we have the right to appoint one member of VM7’s board of directors until the sooner of VM7 having paid the Prepayment Price or having tendered all of the monthly payments;

Johnson’s annual salary as Chief Executive Officer of VM7 shall be $400,000, prorated, for the remainder of the 2023 calendar year, and then adjusted annually to an amount equal to 1% of the Recycling Subsidiaries’ aggregate gross revenues, until the sooner of VM7 having paid the Prepayment Price or having tendered all of the monthly payments;

and (iii) we will receive additional payments from VM7 (that are not related to the on-going monthly payments) that relate to certain taxing agency issues.

Upon settlement of the continuing dispute between ARCA Recycling and the California Business Fee and Tax Division (as to which settlement, there can be no assurance), ARCA Recycling will pay to us 50% of the amount of the reduction between the current assessment and any such settlement.

The payment will be memorialized by a three-year promissory note with interest at five percent per annum.

The first payment under the note will be on the last day of VM7’s fiscal year in which the settlement occurs and the remaining payments each year thereafter.

If ARCA Recycling receives a refund from the agency for payments previously made, it shall pay to us an amount equivalent to 25% of such refund after reduction for the legal fees payable to counsel for this proceeding.

ARCA Recycling and Connexx are due to receive from the Internal Revenue Service two payments in the aggregate amount of approximately $931,000 in connection with the Employee Retention Credit provisions of the Coronavirus Aid, Relief, and Economic Security Act and the Taxpayer Certainty and Disaster Tax Relief Act of 2020.

Those payments are to be tendered to us within 10 days of receipt by ARCA Recycling or Connexx.

To secure VM7’s obligations under the Recycling Purchase Agreement and pursuant to a Stock and Membership Interests Pledge Agreement dated March 19, 2023 (the “Pledge Agreement”), Mr.

Johnson pledged to us all of the capital stock in VM7 (“VM7’s Capital Stock”) and VM7 pledged to us all of the equity interests of the Recycling Subsidiaries (the “Subject Securities”).

Under the terms of the Pledge Agreement, upon an Event of Default (as defined in the Pledge Agreement), among other remedies in our favor, we may foreclose on any or all of VM7’s Capital Stock and the Subject Securities.

We may also cause the ownership of VM7’s Capital Stock and of the Subject Securities to be transferred to us automatically, pursuant to an irrevocable transfer entered in our favor, as referenced in the Pledge Agreement.

In the event of an automatic transfer, all of the monthly payments previously made by VM7 pursuant to the terms of the Recycling Purchase Agreement will then be characterized as contributions to the capital of the Company without dilution of the Company’s capital stock.

The parties have made customary representations, warranties, covenants, and indemnities in connection with the Disposition Transaction.

The Recycling Purchase Agreement contains certain representations and warranties that the parties made to each other as of the date of the Recycling Purchase Agreement or such other date as explicitly referenced therein.

The representations and warranties were made solely for purposes of the Recycling Purchase Agreement and (i) are subject to limitations agreed by the parties in negotiating the terms and conditions thereof, (ii) may not be accurate or complete as of any specified date, (iii) will be qualified by the underlying disclosure schedules, (iv) may be subject to a contractual standard of materiality different from those generally applicable to investors, and (v) may have been used for the purpose of allocating risk among the parties thereto, rather than for establishing any matters as facts.

Information concerning the subject matter of the representations and warranties may change after March 8, 2023, and subsequent information may or may not be fully reflected in ALT5 Sigma Corporation’s public disclosures.

For the foregoing reasons, the representations and warranties contained in the Recycling Purchase Agreement should not be relied upon as statements of factual information.

Subsequent to the closing of the Disposition Transaction, VM7 determined that, after expending significant amounts of time and resources, it was unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries.

Accordingly, we were advised that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased.

Because we did not receive all of the economic benefits of the Disposition Transaction and understand

that we will not receive any future benefits of the Disposition Transaction, we determined to fully impair the approximately $5.3 million carrying value of the Disposition Transaction on our balance sheet.

We also determined not to exercise any of our remedies under the Recycling Purchase Agreement so that we could maintain our focus on our clinical-stage biopharmaceutical activities.

Corporate and Other

Our corporate and other segment consists of certain corporate general and administrative costs.

As of December 28, 2024, the Company had 10 employees, all of whom were full-time.

also hold clinical-stage biopharmaceutical assets focused on novel, non-opioid,

and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction.

JAN101 (formerly known as

TV1001SR) is a potential treatment for PAD, a vascular disease that affects more than 8.5 million people in the U.S.

and more than 60

million people worldwide.

We expect to commence Phase IIb/III clinical trials for the treatment of PAD in 2026.

We are also working with

a novel formulation of Low-dose naltrexone (“LDN”) that we call JAN123, which includes a biphasic release of the drug candidate.

The release properties of JAN123 provide for an immediate release of a portion of the product with a slow, sustained release of the remaining

drug candidate.

Importantly, the rapid release of LDN has been reported to lead to vivid and lucid unpleasant dreams, which should be

eliminated with the formulation of JAN123.

Initially, we expect that a single tablet of JAN123 will be administered orally, once a day

before sleep, with eventual titration up to two tablets before sleep.

the fourth quarter of our 2024 fiscal year, our board of directors (the “Board”) determined that we would form a new

subsidiary and capitalize it with JAN123 and certain of our other biopharma assets.

Accordingly, we incorporated a Nevada corporation

known as Alyea Therapeutics Corporation (“Alyea”).

During fiscal 2025, the Company announced its intent formally to separate

Alyea into a separate company, although we continue to expend corporate resources for Alyea and have not made any decision as to how the

separation will be effectuated.

As a result, our financial statements show our biopharmaceutical segment as a discontinued operation.

Corporate and Other segment consists of certain corporate general and administrative costs.

of December 27, 2025, the Company had 16 employees, 15 of whom were full-time, and one was part-time.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business